<SEC-DOCUMENT>0001193125-11-255976.txt : 20110926
<SEC-HEADER>0001193125-11-255976.hdr.sgml : 20110926
<ACCEPTANCE-DATETIME>20110926112758
ACCESSION NUMBER:		0001193125-11-255976
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		8
CONFORMED PERIOD OF REPORT:	20110831
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20110926
DATE AS OF CHANGE:		20110926

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			DELCATH SYSTEMS INC
		CENTRAL INDEX KEY:			0000872912
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				061245881
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-16133
		FILM NUMBER:		111106615

	BUSINESS ADDRESS:	
		STREET 1:		810 SEVENTH AVENUE
		STREET 2:		FL 35
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019
		BUSINESS PHONE:		212-489-2100

	MAIL ADDRESS:	
		STREET 1:		810 SEVENTH AVENUE
		STREET 2:		FL 35
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d234488d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Washington, D.C. 20549 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM 8-K
</B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><B>CURRENT REPORT </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Pursuant to Section&nbsp;13 or 15(d) of the </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Securities Exchange Act of
1934 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Date of Report (Date of earliest event reported): September&nbsp;26, 2011 (August 31, 2011) </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>DELCATH SYSTEMS, INC. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact Name of Registrant as Specified in Charter) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>001-16133</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>06-1245881</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State of Incorporation)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Commission</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>File Number)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(IRS Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>810 Seventh Avenue </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px;padding-bottom:0px;" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>35<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">th</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> Floor </FONT></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>New York, New York 10019 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of Principal Executive Offices) (Zip
Code) </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Registrant&#146;s telephone number, including area code: (212) 489-2100 </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<I>see</I> General Instruction
A.2. below): </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;5 &#150; Corporate Governance and Management </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;5.02.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
</B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On September&nbsp;26, 2011, Delcath Systems, Inc. (the &#147;Company&#148;) announced the appointment of
Graham G. Miao, M.S., M.B.A., Ph.D., as Executive Vice President, Chief Financial Officer of the Company, effective September&nbsp;26, 2011. Concurrent with, and effective as of Mr.&nbsp;Miao&#146;s start date, David McDonald, the Company&#146;s
current Executive Vice President, Chief Financial Officer will serve as Executive Vice President, Business Development of the Company. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;Miao, age 47, has extensive financial and management experience in global business operations in the United States, Asia and Europe. He most recently served, since 2009, as Chief of Staff of the
Global CFO Organization at The Dun&nbsp;&amp; Bradstreet Corporation (NYSE: DNB). From 2007 to 2009, he served as Executive Vice President and Chief Financial Officer of Pagoda Pharmaceuticals Inc., a specialty pharmaceutical and medical device
company; and, from 2004-2007, he served as Vice President, Strategic Planning and Financial Analysis, Global Flavors of Symrise Inc, a supplier of flavoring and fragrance products. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In his role as Executive Vice President, Chief Financial Officer, Mr.&nbsp;Miao will receive an initial base salary of $325,000 per year.
Mr.&nbsp;Miao will be paid a $100,000 special one-time bonus, which is subject to forfeiture, on a pro-rata basis, if his employment is terminated for cause or he resigns prior to the first anniversary of his employment. On Mr.&nbsp;Miao&#146;s
start date, he received 25,000 shares of restricted stock and was granted a stock option to purchase 100,000 shares of common stock, pursuant to the Company&#146;s 2009 Stock Incentive Plan, as amended. Mr.&nbsp;Miao will also be eligible to receive
an annual cash incentive bonus pursuant to Delcath&#146;s Annual Incentive Plan, with a target annual incentive opportunity of 40% of his base salary (pro-rated for the fiscal year ending December&nbsp;31, 2011). Although Mr.&nbsp;Miao&#146;s
employment is &#147;at-will&#148;, in the event the Company terminates Mr.&nbsp;Miao&#146;s employment other than for cause, he is entitled to a severance payment equal to his then annual base salary, payable over a period of 12-months, the
continuation of group health coverage for a period of 12-months, plus payment of his annual incentive bonus earned for the immediately preceding completed calendar year (&#147;Severance Benefits&#148;), provided, that in order to receive the
&#147;Severance Benefits&#148;, Mr.&nbsp;Miao must execute a general release in favor of the Company. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In connection with his
employment, Mr.&nbsp;Miao also entered into the Company&#146;s standard form of employee confidentiality and restrictive covenant agreement, pursuant to which, Mr.&nbsp;Miao agreed: to an assignment of his inventions and discoveries to the Company;
not to disclose or otherwise use the Company&#146;s confidential information either during his employment with the Company or at any time after termination, except as permitted in the agreement; not to compete with the Company during the term of his
employment and for a period of one year thereafter; and not to solicit the Company&#146;s customers or employees for a period of one year following termination of Mr.&nbsp;Miao&#146;s employment with the Company. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The foregoing description of the terms of Mr.&nbsp;Miao&#146;s employment with the Company is qualified in its entirety by reference to
the employment offer letter between the Company and Mr.&nbsp;Miao, dated August&nbsp;31, 2011, and by reference to the form of employee confidentiality and restrictive covenant agreement, the foregoing being attached as Exhibit 10.1 and Exhibit
10.2, respectively, to this Current Report on Form 8-K and incorporated by reference herein. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company issued a press
release dated September&nbsp;26, 2011 announcing the appointment of Mr.&nbsp;Miao, a copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;9 &#150; Financial Statements and Exhibits </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;9.01.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Financial Statements and Exhibits. </B></FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exhibits </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:28pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit<BR>Number</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:39pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Employment Offer Letter between Delcath Systems, Inc. and Graham Miao, Ph.D., dated August 31, 2011</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of Employee Confidentiality and Restrictive Covenant Agreement</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release of Delcath Systems, Inc., dated September 26, 2011</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date: September&nbsp;26, 2011</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">DELCATH SYSTEMS, INC.</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Peter J. Graham</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Peter J. Graham</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Executive Vice President, General Counsel</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">4 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXHIBIT INDEX </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:25pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>No.</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:39pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Employment Offer Letter between Delcath Systems, Inc. and Graham Miao, Ph.D., dated August 31, 2011</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of Employee Confidentiality and Restrictive Covenant Agreement</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release of Delcath Systems, Inc., dated September 26, 2011</FONT></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>d234488dex101.htm
<DESCRIPTION>EMPLOYMENT OFFER LETTER
<TEXT>
<HTML><HEAD>
<TITLE>Employment Offer Letter</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 10.1 </B></FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px">


<IMG SRC="g234488g34x01.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">August&nbsp;29, 2011 </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Graham Miao, Ph.D. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">7 Beth Court </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Randolph, NJ 07869 </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Re:</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Employment Offer</U> </FONT></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dear Graham:
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Delcath Systems, Inc. (&#147;Delcath&#148; or &#147;Company&#148;) is pleased to offer you the position of Executive Vice President, Chief
Financial Officer at the New York, NY location of Delcath. This position reports directly to the Chief Executive Officer. Your start date is September&nbsp;26, 2011. This letter is written to confirm the details of our offer to you. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The terms of your employment offer include the following: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Your initial rate of base salary will be paid at an annualized rate of $325,000 per year. Your base salary will be reviewed periodically and may be increased or
decreased. The base salary is intended to compensate you for all hours worked. Compensation and benefits are subject to applicable taxes, deductions, and withholdings. </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">You will also be eligible to earn an annual performance bonus based upon the achievement of annual performance goals according to the terms of the Company&#146;s annual
incentive plan. Your annual incentive target bonus will be up to 40% of your gross annual base salary. For the calendar year ending December&nbsp;31, 2011, your annual incentive target bonus opportunity will be pro-rated to reflect the period of
your employment with the Company in 2011. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">On your first day of employment with the Company, you will be granted a stock option to purchase 100,000 shares of the Company&#146;s common stock at a
price per share equal to the closing price on the date of grant (&#147;Option&#148;). The Option will be granted under and subject to the 2009 Stock Incentive Plan (&#147;2009 Plan&#148;) and shall be subject to the terms of the 2009 Plan and such
further terms and conditions as set forth in a written stock option grant letter to be provided by the Company to you to evidence the Option. The Option will vest in three (3)&nbsp;equal installments (1/3 each) over a three (3)&nbsp;year period on
the first, second and third anniversary of your employment start date. The Option shall </FONT></P></TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Graham Miao, Ph.D.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Page&nbsp;|&nbsp;<B>
2</B>
</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">August 29, 2011</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR></TABLE> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">
vest in full and become immediately exercisable in the event of a Change of Control (&#147;COC&#148;) as defined in the 2009 Plan if the Option has not otherwise already expired or been
terminated. The Option will be a non-qualified option and is not intended to qualify as an incentive stock option within the meaning of Section&nbsp;422 of the Internal Revenue Code. </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">On your first day of employment with the Company you will also be granted 25,000 shares of restricted stock (the &#147;Restricted Stock Award&#148;). The Restricted
Stock Award shall be granted under the Company&#146;s 2009 Plan and shall be subject to the terms of the 2009 Plan and such further terms and conditions as set forth in a written restricted stock agreement to be provided by the Company to you to
evidence the Restricted Stock Award under the 2009 Plan. The Restricted Stock Award will vest in three (3)&nbsp;equal installments (1/3 each) over a three (3)&nbsp;year period on the first, second and third anniversary of your employment start date.
The Restricted Stock Award shall vest in full in the event of a COC as defined in the 2009 Plan if the Restricted Stock Award has not otherwise already expired or terminated. </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">You will receive a Special One-Time Bonus of $100,000 (&#147;Special Bonus&#148;) payable within your first payroll cycle. If you are terminated for cause or resign
prior to the first anniversary of your date of employment, you shall be obligated to return a pro rata portion of the Special Bonus to the Company based upon the number of days of your employment with the Company prior to the date of termination
divided by 365. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Effective January&nbsp;1, 2012, you will be eligible to earn four (4)&nbsp;weeks of paid vacation annually (which will accrue on a monthly basis), according to the
terms of Delcath&#146;s vacation policy. For the remainder of calendar year 2011, you will be eligible to earn one week of paid vacation. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">You will be entitled to participate in various Company benefit programs. Company benefits may be modified or terminated from time to time in the Company&#146;s sole
discretion. At present, you will be eligible for the following Company benefits, subject to the terms and conditions of the applicable plans or policies: </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Health and Dental insurance; </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">b.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Life, Accidental Death and Dismemberment, Short and Long Term Disability insurance; </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">c.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Participation in the Company&#146;s 401K retirement savings plan; </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">d.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Participation in the pre-tax transit program, if available; </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">e.</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Participation in a Flexible Spending Account. </FONT></P></TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Graham Miao, Ph.D.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Page&nbsp;|&nbsp;<B>
3</B>
</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">August 29, 2011</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR></TABLE> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">
In case of a conflict between any benefit described anywhere in this agreement and the applicable plan or policy, the terms of the applicable plan or policy will control.
</FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Delcath will provide you with temporary housing assistance in New York City not to exceed $3,500 per month for up to twelve (12)&nbsp;months from the start date of your
employment. This amount will be grossed up to cover the applicable taxes. You will be responsible for any rent in excess of $3,500 per month and all other expenses associated with temporary housing. You will also be responsible for identifying and
selecting your apartment and will submit monthly statements to the Company to obtain rent reimbursement. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Your employment will at all times be subject to Delcath&#146;s policies and procedures as in effect from time to time. </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company may terminate your employment at any time and for any or no reason, with or without cause or advance notice, by giving you written notice of such
termination. Similarly, you may terminate your employment with the Company at any time, for any or no reason, upon fourteen (14)&nbsp;days written notice to the Company, during which time you shall provide reasonable transition assistance to the
Company. Your employment with the Company will be as an employee &#147;at will&#148;. As such, no written or verbal statement will be construed to create a real or implied contract of continued employment. </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Notwithstanding the at-will nature of the employment relationship, if you voluntarily resign or your employment is terminated for &#147;cause&#148;, all compensation
and benefits will cease immediately. Additionally, you will receive no additional payments from the Company other than your accrued base salary and accrued and unused vacation benefits earned through the date of your termination.
</FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">If the Company terminates your employment without &#147;cause&#148;, you will be entitled to the following: </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a.</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">severance payments equal to your annual base salary for twelve (12)&nbsp;months (&#147;Severance Payment&#148;), paid in equal installments over the
course of the 12-month period following your employment; provided, however, that in order to receive the Severance Payment and the other benefits described in Sections 12 b. and 12 c. below, you will be required to execute and not rescind a general
release in favor of the Company in a form acceptable to the Company. As used in this agreement, &#147;cause&#148; shall mean, as reasonably determined by the Company based on the information then known to it, that one or more of the following has
occurred: (1)&nbsp;you have committed a crime punishable as a felony; (2)&nbsp;you have engaged in fraud, dishonesty, gross negligence, or other misconduct, including but not limited to use of controlled substances; (3)&nbsp;you have failed to
perform or uphold your responsibilities under this agreement or comply with reasonable directives of the Board; or (4)&nbsp;you have materially breached this agreement or any other agreement with the Company, including but not limited to the
Confidentiality and Restrictive </FONT></P></TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Graham Miao, Ph.D.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Page&nbsp;|&nbsp;<B>
4</B>
</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">August 29, 2011</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR></TABLE> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Covenant Agreement; (5)&nbsp;you have violated a written Company policy, including but not limited to violation of the Code of Ethics; or (6)&nbsp;you have engaged in conduct that reflects poorly
upon you or the Company. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">b.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">continuation of the group health, dental, vision, and prescription drug coverages in which you are enrolled at the time your employment terminates with the Company,
pursuant to the continuation coverage requirements of the Consolidated Omnibus Budget Reconciliation Act (&#147;COBRA&#148;); Company agrees to subsidize 100% of the cost of such COBRA coverage until the twelve month anniversary of the date upon
which your employment with the Company terminates. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">c.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">to the extent the date of your termination of employment occurs after the close of a calendar year but before the bonus payment date for such year, you shall be
eligible to receive any annual incentive bonus award for the completed calendar year to the extent you have earned such award based upon the achievement of objectives in accordance with the terms and conditions of the Company&#146;s annual incentive
plan. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">This offer is conditioned upon your acceptance and agreement to the enclosed Confidentiality and Restrictive Covenant Agreement. Please sign both copies of the
Confidentiality and Restrictive Covenant Agreement and return them to me for signature on behalf of Delcath. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">On your first day, you will be required to complete the U.S. Government Eligibility form (Form I-9) and provide documents that verify your identity and employment
eligibility. Enclosed is a copy of the documents that may be provided to establish your right to work in the United States. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">15.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">This agreement is governed by and will be construed in accordance with the laws of the State of New York. The parties agree that any action relating to this agreement
will be instituted and prosecuted exclusively in a federal or state court located in the State of New York, New York County. Delcath and you irrevocably consent to submit to the personal jurisdiction of the state and federal courts of New York and
agree not to bring any action relating to this agreement in any other court. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">When signed by you, this offer letter will become a legally binding agreement. This agreement (including the Confidentiality and Restrictive Covenant Agreement, the
Stock Option grant letter and the Restricted Stock grant letter referred to above) contains the entire agreement relating to the subject matter hereof. No modification, discharge or waiver of this agreement will be binding on Delcath unless agreed
to in writing signed by an officer of Delcath. This agreement automatically will inure to the benefit of Delcath, its successors and assigns. </FONT></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We are pleased that you will be joining Delcath and are confident your skills and talents will become valued assets to our organization. If you agree with the terms outlined above, please sign below where
indicated whereupon this letter will become a binding agreement. Please </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Graham Miao, Ph.D.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Page&nbsp;|&nbsp;<B>
5</B>
</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">August 29, 2011</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR></TABLE> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
return the original to my attention by September&nbsp;2, 2011, along with the two signed copies of the Employee Confidentiality and Restrictive Covenant Agreement. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">We look forward to having you join our team. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sincerely,</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000">&nbsp;&nbsp;&nbsp;&nbsp;


<IMG SRC="g234488g47v78.jpg" ALT="LOGO">
</P></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Peter Graham</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">EVP, General Counsel &amp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;Global Human Resources</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">I, Graham Miao, Ph.D., agree and accept this offer of employment with Delcath Systems, Inc. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000" ALIGN="center">


<IMG SRC="g234488g56x52.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date:&nbsp;8/31/11</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">(Signature)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>d234488dex102.htm
<DESCRIPTION>FORM OF EMPLOYEE CONFIDENTIALITY AND RESTRICTIVE COVENANT AGREEMENT
<TEXT>
<HTML><HEAD>
<TITLE>Form of Employee Confidentiality and Restrictive Covenant Agreement</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 10.2 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="5"><B>Delcath Systems, Inc. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>EMPLOYEE CONFIDENTIALITY AND RESTRICTIVE
COVENANT AGREEMENT </U></B></FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">AGREEMENT (&#147;Agreement&#148;) made this
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> day of
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> 20<U>&nbsp;&nbsp;&nbsp;&nbsp;</U>, between Delcath Systems, Inc., and its predecessors,
divisions, affiliates, successors, and assigns (the &#147;Company&#148;), and
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>, residing at
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;</U> (&#147;Employee&#148;). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">WHEREAS, the Company wishes to obtain reasonable protection of its confidential
business and technical information which it has developed, acquired and/or is or may be developed or acquired by the Company at substantial expenses, and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">WHEREAS, the Company wishes to obtain reasonable protection against unfair competition during the Employees employment by the Company and following termination of the Employee&#146;s employment by the
Company and to further protect against unfair use of its confidential business and technical information the Company desires to have Employee execute this Agreement, and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">WHEREAS, the Employee is willing to execute this Agreement and grant the Company the benefits of the restrictive covenants contained herein. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For and in consideration of the continued employment of Employee by the Company and compensation and benefits paid to Employee and
hereafter to be paid to Employee by the Company, Employee agrees as follows: </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>NO PRIOR CONFLICTING CONTRACTS</U>. </FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Employee represents that Employee&#146;s employment or potential employment by the Company is not in violation of any contract or covenants to which Employee is a party with any employer, entity, or
person. Employee agrees not to use or disclose in Employee&#146;s work with the Company any secret or confidential information of others, including prior employers, unless such information is rightfully possessed by the Company. </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>DEFINITIONS</U> </FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>(a)
Confidential Information.</I> For purposes of this Agreement, the term &#147;Confidential Information&#148; means information that is not generally known to the public and that is used, developed, or obtained by the Company in connection with its
business, including, but not limited to, information, observations, and data obtained by Employee while employed by the Company thereof concerning (i)&nbsp;the business or affairs of the Company, (ii)&nbsp;products or services, (iii)&nbsp;fees,
costs, compensation, and pricing structures, (iv)&nbsp;designs, (v)&nbsp;specifications (including, but not limited to, supplier specifications); (vi)&nbsp;clinical trial data; (vii)&nbsp;analyses, (viii)&nbsp;drawings, photographs and reports,
(ix)&nbsp;computer software, including operating systems, applications, and program listings, (x)&nbsp;flow charts, manuals, and documentation, (xi)&nbsp;data or data bases, (xii)&nbsp;accounting and business methods, (xiii)&nbsp;inventions,
devices, new developments, methods and processes, whether patentable or unpatentable and whether or not reduced to practice, (xiv)</FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
customers and clients and customer or client lists, (xv)&nbsp;other copyrightable works, (xvi)&nbsp;all production methods, processes, technology, and trade secrets, and (xvii)&nbsp;all similar
and related information in whatever form. Confidential Information will not include any information that has been published (other than a disclosure by Employee in breach of this Agreement) in a form generally available to the public prior to the
date Employee proposes to disclose or use such information. Confidential Information will not be deemed to have been published merely because individual portions of the information have been separately published, but only if all material features
comprising such information have been published in combination. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>(b) Work Product.</I> For purposes of this Agreement, the
term &#147;Work Product&#148; means all inventions, innovations, improvements, technical information, systems, software developments, discoveries, methods, designs, processes, analyses, drawings, reports, service marks, trademarks, trade names,
logos, and all similar or related information (whether patentable or unpatentable, copyrightable, registerable as a trademark, reduced to writing, or otherwise) that relates to the Company&#146;s actual or anticipated business, research and
development, or existing or future products or services and which are conceived, developed, or made by Employee (whether or not during usual business hours, whether or not by the use of the facilities of the Company, and whether or not alone or in
conjunction with any other person) while employed by the Company (including those conceived, developed, or made prior to the effective date of this Agreement) together with all patent applications, letters patent, trademark, trade name and service
mark applications or registrations, copyrights and reissues thereof that may be granted for or upon any of the foregoing. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>CONFIDENTIALITY REQUIREMENTS</U>. </FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>(a)</I> Employee acknowledges and agrees that, as a result of the nature of the Company&#146;s business and the nature of Employee&#146;s position with the Company, Employee has been or will come into
contact with, and will have access to, Confidential Information belonging to the Company. Employee acknowledges that the aforementioned Confidential Information is unique and not generally known to the public with respect to the Company and has been
developed, acquired, and compiled by the Company at its great effort and expense. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>(b)</I> Employee further acknowledges
and agrees that any disclosure or use of the Company&#146;s Confidential Information by Employee, other than in connection with the Company&#146;s business or as specifically authorized by the Company, will be or may become highly detrimental to the
business of the Company, and serious loss of business and damage to the Company will or may result. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>(c)</I> Accordingly,
Employee agrees to hold all Confidential Information in the strictest confidence and agrees to safeguard and not use, disclose, divulge or reveal the Company&#146;s Confidential Information to any person, either during Employee&#146;s employment or
at any time after the termination of Employee&#146;s employment with the Company, without specific prior written authorization from an executive officer of the Company. If Employee is an executive officer of the Company, Employee must obtain prior
written authorization from the Chief Executive Officer. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>(d)</I> Employee further agrees to promptly deliver to the
Company, upon the termination of Employee&#146;s employment with the Company, or at any other time as the Company </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
may so request, all Company property, including but not limited to laptops, personal digital assistants (PDAs), and cell phones, and all documentation, memoranda, notes, customer lists, records,
reports, blueprints, software, drawings, computer disks, programs, and any other documents (and all copies thereof) containing Confidential Information or relating to the Company&#146;s business and any property associated therewith, which Employee
may then possess or have under Employee&#146;s control. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>WORK PRODUCT REQUIREMENTS</U>. </FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>(a)</I> All Work Product that Employee may have conceived, developed, made, discovered, invented or originated during his/her
employment by the Company prior to the Effective Date, during Employee&#146;s employment with the Company, or at any time in the period of twelve (12)&nbsp;months after termination of Employee&#146;s employment, shall be deemed work for hire and
shall be the exclusive property of the Company, as applicable. Employee hereby assigns all of Employee&#146;s right, title, and interest in and to such Work Product to the Company, including all intellectual property rights therein. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>(b)</I> Employee shall promptly disclose all Work Product to the Company, shall execute at the request of the Company any assignments
or other documents the Company may deem necessary to protect or perfect its rights therein, and shall assist the Company, at the Company&#146;s expense, in obtaining, defending, and enforcing the Company&#146;s rights therein. Employee hereby
appoints the Company as Employee&#146;s attorney-in-fact to execute on Employee&#146;s behalf any assignments or other documents deemed necessary by the Company to protect or perfect the Company&#146;s rights to any Work Product. </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>NON-COMPETITION</U>. </FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>(a)</I> Employee acknowledges and agrees that the Company has invested and will invest substantial time, effort, resources and finances
in the research, development and commercialization of the Company&#146;s product(s) and is engaged in a highly competitive business and that, by virtue of the position in which Employee is employed, he or she will help create and will be given
access to Confidential Information. If the Employee engages in any business that is competitive with the Company it will cause great and irreparable harm to the Company, the monetary loss from which would be difficult, if not impossible, to measure.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>(b)</I> Consequently, Employee covenants and agrees that so long as Employee is employed by the Company, and for a period
of one (1)&nbsp;year following termination of Employee&#146;s employment with the Company, whether such termination is voluntary or involuntary, Employee will not, directly or indirectly (whether as an individual for Employee&#146;s own account, or
as a partner, joint venturer, employee, agent, consultant or sales representative, officer, director or shareholder of any entity or otherwise), engage in, enter the employ of, render any services to, have any ownership interest in, nor participate
in the financing, operation, management or control of, any Competing Business, or in any manner compete with the Company, in any country in which the Company does business, without the Company&#146;s specific written consent to do so.
&#147;Competing Business&#148; shall mean any enterprise, activity, or business that competes with the Company in any of its or their material businesses, including, without limitation, the research, design, development, identification, manufacture,
marketing, or sales of targeted regional cancer or infectious disease drug delivery systems. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The restrictions contained in this section shall not prevent Employee from accepting employment with a large
diversified organization with separate and distinct divisions that do not compete, directly or indirectly, with the Company, as long as prior to accepting such employment the Company receives separate written assurances from the prospective employer
and from Employee, satisfactory to the Company, to the effect that Employee will not render any services, directly or indirectly, to any division or business unit that competes, directly or indirectly, with the Company. During the restrictive period
set forth in this section, Employee will inform any new employer, prior to accepting employment, of the existence of this Agreement and provide such employer with a copy of this Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Nothing in this Agreement shall be construed to prevent or otherwise restrict or limit the Employee from owning shares and investing (as a passive investor), directly or indirectly, in the stock of any
publicly traded competing corporation whose shares are listed on a national securities exchange or traded in the over-the-counter market, but only if Employee does not own more than an aggregate of one percent (1%)&nbsp;of the outstanding stock of
such corporation. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>NON-SOLICITATION OF CUSTOMERS AND EMPLOYEES</U>. </FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>(a)</I> Employee acknowledges and agrees that, during the course of Employee&#146;s employment by the Company, Employee may come into contact with and become aware of some, most, or all of the
Company&#146;s customers and employees, past, present, and prospective, and their names and addresses, as well as other information about the customers and employees not publicly available. Employee further acknowledges and agrees that the loss of
such customers and employees may cause the Company great and irreparable harm. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>(b)</I> Consequently, Employee covenants
and agrees that, if Employee&#146;s employment with the Company terminates, whether such termination is voluntary or involuntary, Employee will not, for a period of one (1)&nbsp;year following such termination, directly or indirectly (whether as an
individual for Employee&#146;s own account, or as a partner, joint venturer, employee, agent, consultant or sales representative, officer, director or shareholder of any entity or otherwise), solicit or attempt to solicit to do business that would
compete with the Company in any of its or their material businesses, including, without limitation, the research, design, development, identification, manufacture, marketing, or sales of targeted regional cancer or infectious disease drug delivery
systems. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>(c)</I> Employee also agrees that, for a period of one (1)&nbsp;year following termination of Employee&#146;s
employment with the Company, whether such termination is voluntary or involuntary, Employee will not, directly or indirectly (whether as an individual for Employee&#146;s own account, or as a partner, joint venturer, employee, agent, consultant or
sales representative, officer, director or shareholder of any entity or otherwise), solicit or attempt to solicit any then current employee of the Company to leave employee&#146;s employment with the Company to become employed by any person, firm,
corporation, or other entity. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>ENFORCEMENT OF COVENANTS</U>. </FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>(a)</I> Employee acknowledges that a breach by Employee of any of the terms of this Agreement will result in material, irreparable
injury to the Company for which any remedy at law will not be adequate. Moreover, it will not be possible to measure damages for such </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">4 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
injuries precisely and, in the event of such a breach or threat of breach, the Company shall be entitled to obtain a temporary restraining order and/or a preliminary or permanent injunction
restraining Employee from engaging in activities prohibited by this Agreement, together with such other relief as may be required to enforce specifically any of the terms of this Agreement. Employee consents to such temporary, preliminary, or
permanent injunctive relief. Nothing in this Agreement shall be construed as prohibiting the Company from pursuing any other available remedies for breach or threatened breach of this Agreement, including recovery of damages, court costs, and
attorneys&#146; fees. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>(b)</I> If the Company is required to enforce any of its rights hereunder through legal proceedings,
Employee shall reimburse the Company for all reasonable costs, expenses, and attorneys&#146; fees incurred by the Company in connection with the enforcement of its rights hereunder. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>(c)</I> Employee understands and agrees that nothing in this Agreement creates a contract, express or implied, of employment for any
specified period. Employee&#146;s employment may be terminated by Employee or the Company at any time and for any reason or no reason, unless expressly limited by a separate writing executed by both the Company and Employee. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>(d)</I> If one or more provisions of this Agreement is determined by a court of competent jurisdiction to be invalid, illegal, or
unenforceable, Employee agrees the validity, legality, and enforcement of the remaining provisions of the Agreement shall not in any way be affected or impaired. Employee also agrees that the language contained in Sections &#147;3&#148;,
&#147;4&#148;, &#147;5&#148; and &#147;6&#148; of the Agreement is reasonable in scope and that Employee will not raise any issue regarding the reasonableness of the Agreement as a defense in any proceeding to enforce the Agreement. If a court
determines that the language contained in Sections &#147;3&#148;, &#147;4&#148;, &#147;5&#148; and &#147;6&#148; of the Agreement is not reasonable, the parties agree that the court may modify such provisions to the maximum period of restriction,
activities, term, or geographic scope that the court deems reasonable. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>WAIVER OF BREACH</U>. </FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The
waiver by the Company of a breach of any provision of this Agreement by Employee shall not operate or be construed as a waiver of any subsequent breach by Employee, and the failure of the Company to take action against any other employee(s) for
similar breach(es) on their part, shall not be construed as a waiver of a breach by Employee. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>AGREEMENT BINDING</U>. </FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This
Agreement shall be binding upon and inure to the benefit of the successors and assigns of the Company, and the heirs, executors, and administrators of Employee. The Company shall have the right to transfer and assign all or any portion of its rights
and obligations hereunder to any third party. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>APPLICABLE LAW AND CHOICE OF FORUM</U>. </FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">This Agreement shall be governed by and construed in accordance with the laws of the State of New York. The parties, being desirous of having any disputes resolved in a forum having a substantial body of
law and experience with matters contained herein, and the parties </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">5 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
having a substantial connection with the State of New York, agree that any action or proceeding with respect to this Agreement shall be brought in a state or federal court located within the
State of New York. The parties consent to the personal jurisdiction of the state and federal courts of New York should a legal action to enforce this Agreement be necessary. </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>MODIFICATION</U>. </FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This
Agreement may only be modified by the express written consent of both parties. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>ENTIRE AGREEMENT</U>. </FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This
Agreement constitutes the entire understanding between Company and Employee with respect to the subject matter hereof and supersedes and replaces all prior contracts, agreements and understandings related to the same subject matter between the
parties. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>SECTION HEADINGS</U> </FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The
section headings appearing in this Agreement are inserted only as a matter of convenience and in no way define, limit, construe or describe the scope or extent of such section or in any way affect such section. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">I have read and understand this Agreement and I agree to abide by its terms. </FONT></P>
<P STYLE="font-size:24px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>[EMPLOYEE]</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>DELCATH SYSTEMS, INC.</B></FONT></TD></TR>
<TR>
<TD HEIGHT="32"></TD>
<TD HEIGHT="32" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">(Signature)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">(Signature)</FONT></P></TD></TR>
<TR>
<TD HEIGHT="32"></TD>
<TD HEIGHT="32" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name</FONT></P></TD></TR>
<TR>
<TD HEIGHT="32"></TD>
<TD HEIGHT="32" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Witness</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title</FONT></P></TD></TR>
<TR>
<TD HEIGHT="32"></TD>
<TD HEIGHT="32" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date</FONT></P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">6 </FONT></P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>4
<FILENAME>d234488dex991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML><HEAD>
<TITLE>Press Release</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g234488g64o35.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>DELCATH EXPANDS SENIOR MANAGEMENT TEAM </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Graham G. Miao Appointed Chief Financial Officer; David McDonald Appointed </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Executive Vice President, Business Development </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">NEW YORK, NY &#150; September&nbsp;26, 2011 &#151; Delcath Systems, Inc. (NASDAQ: DCTH) today announced the appointment of Graham G. Miao, M.S, MBA, Ph.D., 47, to the position of Executive Vice President,
Chief Financial Officer (CFO). Concurrent with this appointment, David McDonald, 51, Delcath&#146;s CFO since 2009, will assume the newly created role of Executive Vice President, Business Development. Mr.&nbsp;Miao will report directly to Eamonn P.
Hobbs, President&nbsp;&amp; CEO, and Mr.&nbsp;McDonald will continue to report to Mr.&nbsp;Hobbs. Both appointments are effective as of September&nbsp;26, 2011. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;Miao is a senior financial executive with extensive experience in global business operations, financial planning and analysis, and business development in the United States, Asia and Europe. He
joins Delcath from Dun&nbsp;&amp; Bradstreet Corporation, where he served as Chief of Staff of the Global CFO Organization and member of the Financial Leadership team since 2009. Previously, Mr.&nbsp;Miao was Executive Vice President&nbsp;&amp; CFO
of Pagoda Pharmaceuticals&#151;a Shanghai-based specialty pharmaceuticals and medical device company focused in urology and allergy. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Prior to
joining Pagoda, Mr.&nbsp;Miao was Vice President of Strategic Planning&nbsp;&amp; Financial Analysis at Symrise Inc., a German supplier of flavoring and fragrance products. In this role Mr.&nbsp;Miao served as division-CFO responsible for driving
profitable growth of a $700 million business line. Mr.&nbsp;Miao was also Senior Director for Global Primary Care and Global Medical Affairs at Schering-Plough Corporation, serving as the division-CFO for the company&#146;s $3 billion primary care
pharmaceuticals franchise. Prior to his time at Schering-Plough, Mr.&nbsp;Miao was at Pharmacia Corporation, serving as Director-Head of Finance for Pharmacia&#146;s $1.3 billion Global Oncology franchise. In this role, he reported operationally to
Gabriel Leung, then Head of Global Oncology franchise for Pharmacia and current member of the Delcath Board of Directors. Earlier in his career, Mr.&nbsp;Miao worked as a biotechnology analyst at J.P. Morgan and Company. Mr.&nbsp;Miao earned a Ph.D.
in Biological Sciences and an M.B.A. from Columbia University, an M.S. in molecular biology from Arizona State University, and a B.S. in biochemistry from Fudan University in Shanghai, China. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px;padding-bottom:0px;"><FONT STYLE="font-family:Times New Roman" SIZE="2">Commenting on the appointments, Mr.&nbsp;Hobbs said, &#147;The timing of Graham Miao&#146;s appointment as CFO is part of the planned
expansion of our executive leadership team in advance of the expected commercial launch of our Hepatic CHEMOSAT<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>
Delivery System at the end of this year. Graham&#146;s deep background in global financial operations and management, and track record of building high performance finance organizations, </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
make him ideally suited to help complete the next phase of our transition to a fully commercial enterprise. His knowledge of the global pharmaceutical industry landscape and experience in both
established and development stage pharmaceutical/medical device companies will bring additional strategic insights as well. We are pleased to welcome Graham to the Delcath team.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;Hobbs continued, &#147;We are also pleased to appoint Dave McDonald to the newly created position of Executive Vice President, Business Development. Dave&#146;s considerable investment banking
experience and skill set are well suited for this important new role. Dave will now be able to focus exclusively on the strategic development and partnering opportunities vital to the successful launch of CHEMOSAT in the EU and other foreign
markets, as well as the long-term expansion of available markets for chemosaturation therapy. Dave&#146;s contributions as CFO during the past two years have been immeasurable, not the least of which was successfully raising almost $100 million in
new capital during a volatile and challenging period for the equity markets. We are confident that in his new capacity his skills and leadership will continue to help drive Delcath&#146;s long-term success.&#148; </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I><U>About Delcath Systems</U> </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Delcath Systems, Inc. is a development stage specialty pharmaceutical and medical device company focused on oncology. Delcath&#146;s proprietary system
for chemosaturation is designed to administer high dose chemotherapy and other therapeutic agents to diseased organs or regions of the body, while controlling the systemic exposure of those agents. The Company&#146;s initial focus is on the
treatment of primary and metastatic liver cancers. In 2010, Delcath concluded a Phase III metastatic melanoma study, and the Company recently completed a multi-arm Phase II trial to treat other liver cancers. The Company obtained authorization to
affix a CE Mark for the Hepatic CHEMOSAT delivery system in April 2011. The Company has not yet received FDA approval for commercial sale of its system in the United States. For more information, please visit the Company&#146;s website at
<U>http://www.delcath.com/</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements
made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such
differences include, but are not limited to, uncertainties relating to our ability and the time required to build inventory and establish commercial operations in Europe, adoption, use and resulting sales for the Hepatic CHEMOSAT delivery system in
the EEA, if any, our ability to successfully commercialize the chemosaturation system and the potential of the chemosaturation system as a treatment for patients with terminal metastatic disease in the liver, acceptability of the Phase III clinical
trial data by the FDA, our ability to address the issues raised in the Refusal to File letter received from the FDA and the timing of our re-submission of our NDA, re-submission and acceptance of the Company&#146;s NDA by the FDA, approval of the
Company&#146;s NDA for the treatment of metastatic melanoma to the liver, adoption, use and resulting sales in the United States, if </I></FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>
any, approval of the current or future chemosaturation system for other indications, actions by the FDA or other foreign regulatory agencies, our ability to successfully enter into distribution
and strategic partnership agreements in foreign markets and the corresponding revenue associated with such foreign markets, our ability to obtain reimbursement for the Hepatic CHEMOSAT system in Europe, uncertainties relating to the results from
current or future research and development or clinical trials, and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed
from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or
revise these forward-looking statements to reflect events or circumstances after the date they are made. </I></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Contact Information:</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Investor Contact:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Media Contact:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Doug Sherk/Gregory Gin</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Janine McCargo</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">EVC Group</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">EVC Group</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">415-568-4887/646-445-4801</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">646-688-0425</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g234488g34x01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g234488g34x01.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`3P#W`P$1``(1`0,1`?_$`+4````&`@,!````````
M```````&!P@)"@$%`@,$"P$``04!`0````````````````(#!`4&`0<0```&
M`00!`P,"!`(&"P$```$"`P0%!@<`$1(((1,4"3$B%4$C46$R%G$S\(&A0B07
MD;'!X7)$5"4F)Q@9$0`!`P($!`('!@()!`,````!$0(#``0A,1(%05%A$W$&
M@9&AP2(R%+'10E(C%?#A\6*"LC-#)#06<I*B<V.#-?_:``P#`0`"$0,1`#\`
MOIW)Z]CJA:9",.9.18UR<>1ZA2D,*;YK%NEVAP*J`IF$JZ91V,`E']?&E1H9
MHV'$.>!ZZZ,ZIRI_*UWG+&LUBYO5.JLV;F5%>EX],<JRJ*)CCL2L%*'(PCM^
M@;CMKT)VS6`)!@CP/.3[ZSLL]^YQ`DT@$Y`'UK743Y6>]AP$P9Q5^PYN?_PG
M'H;@!1W)M_;&Q1*(@.^WTUS]FL,C#$#U=)33;J^CQ=*7+S:T?92_XG^;+LW3
MUF2&2(BDY8B$DDTW7NXW^SK&NDFY55<.DIB``8@SU5!0J1.3#T2@0!,43")M
M09O+EI)A&YS'`XYG^=.'<;V`!S]+P>F563^N_8O&?9[',=DO%LL>1AW!B,I9
M@[1.UF*U/E9M'CVO3;0X;)2+`CTG(R9E$%`'DF<P>=9*YM9K24Q3#(X'F.=7
M%G>07L9=$?U&.TN;Q:Y%0^NEVU'ZU*H:XHHH:[1577N_\A7;'$G;7-F-,?9<
M<U^F4^P0S.'B/[6ILB6/2=TZM2JK<CF0KSR07(H\?JJ;J*',`GV`0*``&SV_
M:+":QBFD:XR.:2?6:SUW<WGU3HXY"QC>30?MJ47XH.P^6>R6"L@7#+]K5N$[
M"9?EZO%RBL7#Q)DH5M4J=*)L_;PD?&M3@B^E5QYF(90>6PCL``%)O=E#87G8
MA73I!QZXX5,VFXGGB?\`4.U.:\@%$)'6I1=4ZI5K0UQ116-_]-AUVBLZ**&^
M@8T4-%%0]Y\^9/`V([+=J#5J5>L@W>DV::J+X.,57JDI+PAW+-XJUG%GL@_>
ML$)1OZ(F39`8X;G)N&V]W;^7I[H!TK@QB`C`G/A5-=;W;6DKH4U2,=I*'HJK
M[*D$ZLYL7[&8`QEFMU7B5-QD*"7F%*ZF_-*)Q9D):1B_13D#MF9W1%/8>H!A
M2((`?80\:KKVT=8W;[1Q#G,(Q`3,`BK"UN!<P,G(0O"I5;7M'\F/;ZE]E,XT
MRBY>/!T^H9*MM4@H=.KT=\DP:5Z9=Q2:!7CZONGJA@!KN<55#GY;[CK8P[-M
M,EK;O:'.F="KT/XE_@52W>XWT5Q)#'ITQO0%,\%J:SXL\ZY-[$=7"Y%RW9CV
MVX?\R\@5X\L>/B8PWXN%?M$XQI[:%9L&7%NBL.QO2`YN7D1\#K,[U;V]I?F"
MV!;%I!0E2O'&K+;)YI[423E7ZCPJ1W?_`!U4KPJQK.NT4-%%#110T44-%%#1
M10T44-%%#110T443\AB):!>#%,)#%I]F$#AON00A7P@8-A`=RCYT_:_[N'_V
MM^VNBOG;)K+!$QYBKIE5&/1.`$WY\@0#<"B83$]0HAL`[[AKVHL;J.`SK.%T
M9>[0\.*G+AC5V?K'UQPAEKI?UQ:Y(Q;4[0$]@S%4A-FDXE!)[(2)JC#N#/WC
MMC[5<[\SC]P5`-R$_G?7E=YO&Y0[A,V*9X1Y'`A`3A5JVTB<P=P:L/"JQ/R,
M];ZEU.[1S&,,=OY!S3)"I5>]0#"4>J2$G`-[`I+,',.]?*))J/$DY&!<*H*"
M!C^@J0IS&,43#O-EW&3=K3ZFX:/J`=+B$1Q`P('#X4!'/&JV:(13F,%6@*%J
M0'X',@2,-DGL?3WD@5K2AQO6LA29GAQ*R82-?GG<,I)>Y55*@S*$/)*^Y$2;
MJ$03$3;)@&LWYI@6.$Q#5,9-('0IA]U2=N$39'Z``2%*<>II-^W?S%9LR'9;
MA6,"S2.+,51[B5@H^=BB-'5VN$>5P@BE9%)]PBH-;3?>T4.T38"DJ1JY_=4,
MH`"6;MWEJULF-DOP9;E?[(Z$<:AWLU]++IA>UMKD1^(^!IGLMDGOSC"NU/,\
M[;>S=2IL^LR<U2\3MBO1*W*N9)B9W&J-E9=ZYBW*<@U<^HW!4@I.2;B0#\?%
MD++9KEQC:8)'A3I8`".:^&50HX;@N_3DDPY@CU%:E\^,+Y/<GYARS"];\ZNV
MUK=V*NR)J!?TXXK*P+3-88.99[%6T69?8RAY6";+*I/03;F*LUX*`H98!+GO
M,&P6]K;&_LU8QK@K#CG@H/"K:VO)VS-@N"'!^`(P0@+CXU$+\G#XA._79D4W
M8*#_`'=7T^2:O[:9D\>4U%1(W#[#G1.D)3`.XE,`@.P@(:N-G8YFVP.7!T9_
MO5'W.8P7/Z!:Z0@*#BG\&IDOB.R)$X"^.O.V<KJU%I5*WDK(US26,LFU&RIP
M%4J$,1E'N%U%2"\E+'&C%H")0`78@4"C^N>\QL9=;Q%;0.60QM:3U7$GP7U4
MO:7F*SEN'@_%(7)Z`$]=1*YZ^4?MGGN1D2C?Y#%M,<NC.(ZDXY>*ULC%L1PF
MNS;/;.P%"RS+I#T2BJJHY(FJ<3;)%(($#36OEW;K6("1A?,<RH]B\*9N9+BY
M>"7Z6<`,,:26"[,]LJHBVMD9FO.$6DY27_'3SR[6]['.$U$!1<BQ4E7KR+>`
MW*X#F8"*>D)BC]IMM21LMM<_!V@X#@`,/%!4*4N@1SIBW'J?LJRIF/MUDBA?
M%K0^Q\3/"GF"Y8_PZWB;,UAV,LS_`+QM[^":OI-[&2!%6*C=ZU*Z`=TE/WUB
M\2;B`!B+7;(;GS`ZP*"T:7$XXHT$H#[*OX9'NVX7#E,NGAT*!!U'KJ')PE\N
M?9)!&7*7L@O`/11GH]VS=O\`'%?4!^)/;&C$6*];,JV,103E33`Z2)4Q`_`V
MP&U+QY=M$`-JQZ(45Y]*X`^'&H0;N$P!4D9\J9K7NW_<#!M_?>EF?+$'<JK)
MRU<EHBUV67M#9L^CGJC24BIBNVMQ,1+D$'S38Q5$1,4Z8;&#3S]IL[Q@0-TY
MX`!5J`Z&52YL\D<S<D(./)P/"IE,V]_L^Y'^.7!N6J$K<*=F&WY>?TBSV?'4
M1*HD=$Q\VL)I>2:,THV02+"VM-JW.L!#"V;NP41*8?2$@4%ILU@-ZFMYW@6K
M&AS0[B20$_E5TRXG-D-)68X:B.7&JX4Q+/I&1?2KYTH\?24@\E)!\LH'-X\D
M'"CIV]6_IY'<N%C'-L`>1'P&MXV.-H#6@:1E5-,8H_B+6N>3CAQYU,M\6N:^
MVL]V;Z^XG<7/+"V"HF.LRB]35CEV=#;5*&HLXK%<G"L4V:KQI9AVS.B8JYSK
M+&(8.7D=8_?+/9_HIKACO]<'#BI))0@\L*G6<T[I8XW?X/!`@PY^%1U]U!*'
M<#M*FDB+7_[]RF4B1U#*E*(VJ1,*A1#?F594PJ</]WEM^FVK3:VZ=KMY``"Z
M/WT[N&@7A&":1ZZZ*SVY[`T3$$;@NB9*L-#QO'S$W9U8^EKFK\Y+34ZY%_+N
MIJRQPHS;MF10"^D@59-%$A`W`1#?3USM-K)-]4&:[@@`KB$Z!"GC48RB-@:7
MZ&*O''U5O,?]T^S^.["SLU7SSE$DLT,B0"3MPG+/$ND$W35X9G)PEA>R<6_9
M.#,R`H0R8&.3<O(`,.N3;'930F/M@.(SY'I0V>9N-O*'$YKCA5QKHSV8#MEU
MPI66W3-M'6-923J]T8,U!.U0M]6<A&S#AJ04DO;-)C9-^@ANH+=!T1,3G$HF
M'S3<+-VWW;K5Y#B,5'+A5Y;2F>$2.0.XI3O-0Z?K6R4O'Q*0*OW2;<IN0$`P
M_N*B4-S%23#<Z@@`_H'C3]K;3WDG:MFESP%/0<S2'O#,Z3Q7*;`JPIHQSA0I
M?ZC*+)I^!$=MMBJ!N)0`?(_KK0Q^5+MV+YF#HAJ.;KDVM]$WV%DU2(G%1D=0
M1*0SDR8(B8"\@**H&``,8`';<``=OYZ@7>PWUHPR%'M'+/Q2G8INX2$(3G1V
M*8#``E'<!\@(?00_B`_J`ZI5Q3C3U9UVBAHHH:**&BBF]=MI!]%=6NQDG&.7
M3.088/RD[9.V(G*\;.D*7,J(+MC)J)'*NDH4#%$#%$!#ZAJ58_[V'_VL_O"F
M;C_`=X5\_P`EP60C'2C)4H'2C7)T1`.&QR,E#IB7]"B4X!_+QKV*=SFD:3^*
MLE::6O?D/Z:^A5B)&NT;!>+VH#'5JLUK%U+0*+ERBRBH:+CZO&D#UWCI4J#=
MJU13\G.<"@`;B.O&I]<EX]C&N=(Z1V0)XFM>'M;&TN(`053B^37/5>[(]P;U
M<Z*^9RE'K,/7,:5:<8>L*5C:U;\BYDIQ)8YQ(NS=V&<>$:J)E*15HDD<`'ER
M'TWR_:.L;`02A)G'4[HO#T<>M9^_NX>[W(2'<,.E&WHO'6JL]?ODGRG">NS1
MBNMD902S)FR+N/*^MEA<*R40=-PIN=\O`I'VXI&]$BP'$Y3&3`T/=WC]QM+9
MP`E$X*<4X&E6#>T)9L2#$1_W<NHJ-,C185$6Z*B21A5;$()R^JD)SJD20*<%
M04()14,`"!@,'GSXUI;@L!_4<&XG,+4*&9SQH&!:!TJ82]=:?E_R-2AQS>4,
MH6^@N6\8W6I\I*T\U?30AU$%HA-K&I';I1WXQ1HF*(H>F*0$`"[%$0U103^5
MX)C-!<VL=QBI`E7'/-J8]/LI\,WN`Z@XR,=D$4"O?TX^.ON+COM9@"^VS$$Q
M7JK3LE0EALLT[E8<C=A"QY'1WZHF)**KJ"=,W`$R%$5>7``$#::WG<MKDVN6
M"&ZCF>YN#6APQ&68%+;!>2SQ%T;FI(UQ*\BI]=1]]V2E?]Q^TSED[:OVSC.N
M13(N&Z@N&ZB9I]R'[*VP%$I%0$AN.Y>91V$0\ZF[;$[]MMXT201J5PS-/WTD
M#K]P:6Z@T+ZZDIF9-8/@7J<='/\`T3HYZ/7IC\8V/&E>%',M@D%F,L=%^(S0
M&]1$RBJ@;*&3(`I?M@;5';M)\VO"#4&.3HC:DP!O[>\)S2HP^H=3K5O[5]=*
MED.*BK!2;3EJI5ZSPDX8H0\G#23E5!1G(<U44C-UU1(42";]PP@3R([#H-X(
M&U2S8]YK%:1P)S-4T$_<NXFNP`=_*KYZU"HKFOH55W3*JYK#6/4BD*\YKL2O
M!MXQ9(B"\>E%*M#L4V2J*92G2`@$,4H`(#MKR9MQ.TZ@]P><R"1]AK6.C8?F
M#3ZJBI^1/Y#Z[T\3K6$<7X_J%LR&M"0]@/"V.-`F.Z+3@7>,X+E%Q*[%5:96
M<10G8M$?21;H(^H<P<DRFT6P;+)NFJ[N'/9`"F!^)QXX^%1;J4P,:(M*DY'E
MX5`S=^^'R!]HK,K5ZYDN^J.YIBHV)CS!D.^ADUH\YB*KBBQJZ#FR+E1.(;N5
M'2BR91`HJ;>!U$6Q[/;P'4QC0PDN>YQX\]7N%57U5RYR2.4<A3`K36K37+1/
MUJXINF=JB)N3861I)*G6DV\Z@Y53DT9-<ZJZBC])\4X+&$YQ,IN(B([CJ]MS
M"Z,.@30@1.(X)TJJGC[?Q`J2:M^?%]&KUGXP:H]?$2C1?U_-EE(^*LF@1RQ=
MVBY*L9@[D3!Z7-BW3$ISB`D(0-_`!KS/>G%WF`M"D]QH3U85J=L'^E:<$)SJ
MG(DV<KQS-5P8Y51:I&7]0O,RB@H%$_,VY1$^XCR\;[Z]2'!:RCHG33/&I$<?
MM-7SN@YC'Z3]4S'$3".!,8^1$Q@V_M6-`NQCB(B7B`;>?IKQW="/W*=,NZ?M
M-:K;FI91`C)OOJD1G568G,^9QF)ER5W(R&:<J.)%V82F4<.!O4^4RH@0^QS&
M(0-Q#Z[;Z]1L&-^FCC3]-L;4'`*!5'>QF7<)E<@80WQP7^56?/AUZJ8A8]4(
M/,L]5:[<KUF@;@C.2L_#LY08NJQ=EFJDWIT8F^*[1;QRZ,2HN\,F4AW:B_%3
M<J9`#%>9=TN_W%UI;O<RWA("`D$E`545<;?`T1:W?$N&.-5=LJ5MA6<M97KE
M=24;0<!DZ^0<(U<'.JLUC8BW3$6Q:'65,*BQFK-J0FYMS"`;B(B(ZW5D][XF
MEY)/;;]@JIN)&P.)``)<:MU_#-#M(OH?0G2#0&SJ=NV59:54*"I0>OD[W,0B
M+S@HH<I1/%0[8GV`0AO3Y<0$1W\X\R?_`+,K?RH/8#5MM3"RT"E27$^NI.YV
M70@HQU)N`Y$;IB8"<@**BGT(F41\;F-_LU5VEI+?7#;6#_$>4\*FRR=L`HM(
M*P:SN098SQ8P)L@4$3")S+(,FRIA$&Z/DNYC$*`^/NW^NP:W\\MAY;LOI\[Q
M!T)*9U%8SODXD)C_`"I36=*J\<04G1DW2QO1,I[IPFD(BB/V&*CS#B4>6PAY
M`=_.LE-ON[3G4P(WDT$^WG3\<(A)+C@>=%NR8Z+Z"\C752B([N!9J"!BF*`;
M_P#!J@.Q=@\@`[@/T`=6.U^9I5%MN?Q-5`X8)XTJ6$2@!I3&NS'UH6*L$%)'
M\&*`,#*FV425*7[V@[F'<H\?MV`-A\>0'2O,.U!L1W*V0MS('+@:(Y%)8[`B
MEDUD`5`-/4-=HH:**&BBFB=]Y2:B>FO8]6O0RT_,2&*['7FD4V375<N`M22=
M9=*MDFR2RRKADSEU%R%`H@8R0`/C?4_:F-DW*%KBC=8]F/NJ+>O[=J]V>%4C
MW>"\L"`H'QS=7*`I@W.4]<E!`R1B<>!@%N)3BH'C;]=]M>RNM)0CG#4#_7C]
M?SUA8[B-[CJ;*/[)YTJDV3M];*^A5;7*9[LM88I@HA7[#,723@VZ,:Q513XQ
ML@Y48$191Z9DR%`O$"!L`?35;'MDT<IDCB8UZX$.C7^]3[IHG!'&4@=#2RX%
M^,_MMG"PMH]#&DWC6"4*FN\N^38]_6H*.042;.4S-V:R'YF;7<-'93HD:('3
M.`"`JDV$0C7>[;581.D?.'SY!C?B)=Q!.03G3L%A<7$H:UKVL.9<$"5:.P5T
M6QOAOJ7-]65G`6%E?("SMLEVX\<U;/[19K@Q.TD[`1J8%B-PB2`BE&)G,H9N
M@S1`3F.!CCYO=;I<W.Z-W'(,>"&DXH"J+]M;"UMVVT`A4N3B:J<]C.@'9;KI
M9Y6!L]`L5HKB4H5E7<BT^%?S%5M+-58"19TEF";EQ%R[PAR>JR<@15);D0@J
M%+ZAO3K/==MW2+O,DC:<RUQ`(/'#EP6LI>6KK*<F368G'`@+CB4HR4'N!W^J
M%3>X9IV7<MMFD"S;`%>&,"8N-8B&"#5%NS82DE#/[=`1S=$B8%2!0A?N$/H.
MHLFS[4]YE[+7N.:N0>(0X^GA2&&\+70VUS*V(MPU`*T]",14ROPX,>Q=VN><
MLP9YN67K`DA$UNE5YOD:=M*C%U)R3]Q8[$]9P$XB2.!6.;M&"22[42>A[A9(
M2?<&V=\U.M(88+>S9`U1J)822.&DKZZG;$)73R.DD>_2T#$$8DG''/*J^&0L
M+Y7<9-R<LWQ_<3%5R1D!0JC2N2QFYDC7*;.B9`Q&RB9TQ2$#%$HB`E$!UO8[
M:;3'.!\+H6`#5'A@#^>H5]=037;Y0U[2I&#>1JRIULZK*YX^(&J]?[5$GKUH
MF*]D"3KIG[/\:]B;Q&Y/MU@I,T\3<I"H@*[Q-N#@YB\C-%C[;;@(>;;A>2[=
MYF?<L(#6R`'B-):`[+TUH[-G>L-`5NKT&JV&4.K/8;"MH=57(.++I`3,89RL
M#MG$R4I"NT(L$UW,O"6>,05B9&,;"8IP<HK<2>!$2F`0#?P7=E>0":UD9)"[
M@",,.(*)69N(W6=P89P]44%H4'T\^=&Z*N?<G,E485*&OG8"\51^Q3KT;'-[
M+=92N+MU72:"+$J@/QB5TV[L2"4BR@@CQ#<2E+X1]/8-U/T6['-:YWQ!H5`J
M=5J.LS%<TR/7@%*5)?\`+=TVR]$6S'.8ZK79^[X_98>QOBNP/(=DM*3<#8*:
MW?1;9:P1\85=T9E--W:0D>`4R)7/)(PEW3$^?\K[A:R02VI>R.Z[A>`2@*\`
M<L*TU[#(R..Z`<XQPAI:J+BN/,\*CQZR=@>UG4YSDV`P9#+1UCN[&!+:0E<;
MFM%FKR<:#M2%DXUL\;'6AO6;R"I#`Y06:K@)!,F)R$,%M=;9:7CV'<7-;&TD
M@:T!7,89U0QW5W`XOMBUKG9J%]%)#9,09_G+79K!<<?Y#D+=/S\M-6=V_K,H
MB]=V"7D%GTP[=$*Q10(Y<23DYCE(4I2F-L``&K4V9CC:VS<QS$R:]F`3#-PI
MJ2:(7!B=W"4#B0W!3FE6NN@V,[!9_C%KF(+3%2M8E+'C_,=$.@_!\A()M;'/
M72,8R1$9OU/:E<MY`JR1`*5J4HAZ903V#7E^\R-M?,8FE+2&3,+BTJ$P7$9D
M?:M:+9F&7:3&I"N<AXYU4FR1@[*N'I:8K61Z19ZJ_KK]*(E!FHB09L4WAS"B
MV.E(JD&.<-9(2<VRJ:IR.4Q`Y!,4=]>H&>WD)FMI&2V[BH+7`G''$8)]]45Q
M!+;7!B/RIGSJ6GXJG':>;[58ZK5ML^9&N+,38MN%B0I]C?W1O2DX4T*A$U**
M9Q"\G&0BK520LR*[,OI.R$33#@F``11+*^8X;:*S,A$(FED:%:07=5PY5*VY
MQGO(V-=(C254%/X)J+BV8JS3:KI=+4[QU<4GT]<K3/216]3E6K0LC.3LC+/O
M:M#H*'0:>Z=&!-/D<4R[%W,(;CIK6UGC8T!JLT`#XV9)A^.H=Q+"Z[DD_5Q)
M":2B@YU<9^-VEO\`&?1/KW!2))$\D%#=6I\SD6(QD@R=W";F;DO"K-%#'.BI
M%GFO:@)]C']+D(%$>(>5;]+W]ZF<P-`,@&>'(GV5K=M.NSC(4*..!SXU3HN.
M-LN72]WRX#BJ],37"^72U?B_P$VY&.&PV23FC-!74;%4<%:>]],%=@]0"\OU
MUZS%9R6\+-+=0T-&#H^0Q^?C63W&]CDN#(&R*I"!IX<:G5QUV%[$]!>@'5!"
MGX;3R$]OSG*-AL3R>C[J^:TUI+6=W8ZM!23:";-7+";DVLPH`IK*`1/VARD!
M3R8N,EVW;]VWN[^IF[886HA:%*(<2H*=*LHKR>PVR"2*-TCY-1(3%O*IEK#:
MIFX4/',G)PKJJSEFKD#8YBI/%TU7T#*2\4V=+0CP[8ZI%5XUTLHB8Q>11,01
M#2/+%LRWN;JX+@ZWC!:')P!74OW5=S'N1,/XB%3Q%'68=%H=/:0\6)$YN03`
M=Q.7U2**E*+QR)]BB8Q/\M,1#?Z>/&H5C"?,>].W"[_V<9Q=F$&0]/&G)W:(
M4&#R,/&B9#U.QV!)5\<>8'*4"+R1CE574Y?N&;JJ%4,8"G3VY;@`CJ^O=\V6
MP<((VZD)P8`@J)%"9L'*"*]T7/SE/D_92/KJM2&)[AFH(JB"!N(>LVV/P*H4
MH;E`/`A]0U%NMIVS>+`W%EA)B0[^MR/OI<3W1DA"G6NS(449C*QMDC#E1:R)
M"&$Q-R^F]*F55)8"@`B3<H%-O]`'</&D^6KD7-E+L]Z"Y[![%0C[J[/$[N]\
M$_$`$\,:7"#DTYB)82*?+BZ;E./(H%'U"B*:O@!$-O5(.VW@0UA[F,P7<EN1
M@QR?QZ*G#Y16VTU7:&BBAHHH;:**&N)10T)16-@UU**SHHH:**UJ<1$H/5I-
M&*CDY)</WGZ3)JF^7\`795V5,JZG@-ON,/C2M3D12E<#6@J`%K8_S_7_`$\:
M37:SKB485C^/C_OT%H1#E176JDDLD=%9)-9%4IDU$5"%424(8!`Q#IF`2'(8
M!V$!#8==:-.#<$H1<ZZ&,='QC<&D:P9QS4#&,#9BU0:-P,;;D8$6Y$TP,;;R
M.WG722[YB37``WY0!7LTE`,J[7A1CH]!XX>H1S-!ZY(0KE\DU;IN7)2CN4B[
M@A`76`@_0#"(!I9>XA"20.M)#&#$`+X5[M).-*K&P?PUQ!17D?1T?)H>UDF+
M.0;<R*>W?-D7:'J$'<BGI."*)\R#]!VW#2@2W%I(KA:'?,`:]!4DB$(F1,A$
MTP`J:9"%*0A2AQ*4A``"E*4/``'T#7#CGC0@&7"NS7$KM8V#^`:[UXT995I)
M=.?5](D,X8-"@8IEEG:"CE0P`/W$33!5(A=P_4=_.I%M](''ZL/+4PTE,>M)
M<'$?`0#X+0ADIQ$JI)EVT>F,;DFJU;>T],-@#@=,%50,&X".^^^^DSOLG._T
MFH<U*TI$HANZ/(/KF6<=+(+Q17::OME%#>H":2!2IE(4"[<"JD`=MPU>L\P0
M6^RC;H!IN"TASNI/MPPJ(;0]ULNH_"XE/&N5JILG8;`R>B*'XY$$$%"F7,18
MC8#@=R"9"D'F90`'CY#83:YMF\P;9MC[5B_5OQ!1&D^%/S0]T`*B&C!:GLM`
MQJ3B'29$8,42@Y]8#*K)I$X))$12,<@"F4-@$>0F_E]1U!VR&RO;SLWSB))#
M\*<7*II$KGQM&@`FB-<UF]AI4?:")@DZ2,F144R\3F246%!9`OJ``B7U]C%`
M1V`!'ZZO=CC?MV^R;."L*E..(&K^5<FQ8.?\JZWBQ)K%K5TH/([)0B:*Q2DW
M3(T6%N._'?8!1`2FVV'?]/&D6FNQ\T/C8?\`$)X+\P]QIKNF6U,Q".:N'-,*
M/6.UC+U&/,42F`@NTT@\@!2)N%2I)F'SN)0\"(?753O\9CW:5IS4+U*#&G;6
M8SPB1P0\JWQD)TRH*`_9)I\P,+<&8G#@`ANGZQERG$1`/KM^NJT.@3%KE\:D
M5N"";B',NQ]ONX^0W_40_D(Z:KJ5SURN5XW""Z@[I/56P;`&Q$T#A_C^XF<?
M.E,<&E2T.\5]U'CE14A+%`6!VY9P5\B9UTS+S>,XB5K\DX:D]04N;E%@9=9N
M7U"B3<X`'+Q]=//?H37"UJY+K'OIMLT<I+6%I(Y$'UXT:/9K_P#KW`AOOL*;
M?;S_``V2#3>L?E%.4`9KE`/^/<"8`+]PIM]MP^H\01`/N_71K;^445CVCKEO
M^1<;;"''TVVP#_'_`"!^G\-<[G_QL];OOHPK/LU]A`7[@=_IN1OX'^(;(AKO
M<!":&#P7WDUTUCVCC??\BYWV'QQ:[?7</`H#]`';7#.,NW&OB['VT5DS1P;8
M/?K@`>?\MO\`4?J([I#I0D:/P-/K^^FI8^Z`%1*X%9.2F$?R+G80``+Z;80`
M0_4=T-QW_AKO>!SCC_\`+[Z3%#VR2I*UQ]B[Y`8)1T`?J7TVH@/\MQ0W`-<^
MH!P[47K=]]*CC+'%Q)*US,S<F$O_`+BZ`H#N(`5N`F\#X$00#8/\-=$S1_EL
M]OO-$C"\("1X5R%HM^CYP4?T$"-Q_3;Z&2$!TG6/RBG!@$K/M7([A[]<`W';
M9-ON&^_C?T=Q`-)$BYM8G1?>317:""H'`WNEA*'^YQ1V'^0B*0CM_MTFBN)V
MZIS`(.UB@`[\0*CL/@?&_I[AI32!F`:*XG;+&$3`^<$#8/M*"&P;!YVY(F$=
MQ_UZ4)`W)C#XK[B*[6NC'+260%U&SZ4NU(NNV,Y8N(]VW!RU6.@Y;BLS*=(J
M[98@D4)OR(8!`0`=*>_2[2Z,-=G^+WFN`@XC&M@9HL(B)'SE/?;P!6XAX_\`
M$@(^=<$C1FQI]?N-%<`9.=MC2+@X^?(D;AM_#8"HAYV_COH,H/\`EL'@OO--
M31]T``HE<P:N`_\`/N#%VV$HD;^?\#%1*(:X9&G\#1Z_>:<`0`41K0WR,W.5
M2J.8N0;^G][21X-7/J@`_P"6N4@(&3/X_J$H@/\`'5QMLNP]LLW-D@D&3FE0
M>B<*;F;*\#LN#2N-<ZFGD!T7UK>:,CBF;$$K*..1TY2="(@<JZX)BW$A`#<!
M(8P&_EIK<#L8#?VIK^XIU%V2<$XJM,VQN]3OJ=.G@@HNR-KF&%S0@57Y4V!W
MK9(RIFZ)UP;NT`,F(_M[`/N#%*!N.P`.XZL8-LM)=D?>Z-5P%3'`)TID.?K(
M<J+75:K7/5NPL6)G1CQ:YVXJ*JHM@7504%,'!D3E`I""@!C;"(!OQ'^&G=GV
MBTW+9Y+AC2^_8J!<,.E./8Z,`EQ*T9;/$3TRU!M%2*3B+D6Z9'`*F0``3,9/
M=1)0I/O35)N81+Y#;QOOJHVN\V^P>)+V-YO(W*WFO542I$D?=:`"B<J+MT(C
M7J@QJZ3@J[QP)1+RXIB<B*WN%E11+]PI'5'@``'^/TU<>7Q/N'F"7=I`EL"2
M!GB0@"^&--W/PQM`/&M8^(HPQ:U26#TE'KE(42D.!!]-9R*Y3\2B']:!1\!O
MX'4BR<RY\X/,:%D8*^@??39C[;!BH-'.@LW/]HM#(/5$3+'?*H@4B)DB\W*O
M`1**?(P"8!,/D-]]4^_S1OWF0EH+&D`C)<!F>=/PQ=O$DD'A6G73S"D\3(FO
M6G+50%!,X*91$&QR<03%1)1,%52+`8=P(`B02_KN&GX[CRD^)VMD[9&MR7,\
M0O"FWLO!BU["/^E*4-DPE09(DD945'P?<X68HD00,;D(E*DFL58Y2<=M]Q'<
M?X?35%)+!W2^"-(2,`XJ?7A1]._\[EK=[#QX\AWX[<O'+?;;E]-M_P#5IA<5
MJ2F"=*;UVRQU?\M=<LO8ZQ9.EK60K73GL;5)@\D\B"(R@+M716JDFP$KIDE*
M(MCM3*%'B4JP\OLY:EV$T5O>QS38PM<IP7#PI$T?=B=$I&H9TQ#XZWW4UJ[0
MHT%AF$P%V_QW7I2H90I4NV>)WN32AU8A*PV5M/N`*%QK<\_6;NR+&,HHD*FP
M%],I%3W?F-F[12&:>43;7(-3'M*MT</`C)$7#C559C;XYVL=&(KT$@`8%W7#
M-1CC3I.VO9BR]8IWKO/.(2OR&(,BY;8XIRE.2"SMM.5!:V,E2TV>A5"O$8T[
M,DJU5*^(X(<?1V,02;&-JNVC;6;E#<-#C]9'%K8T?B`^;#HW$\:E;C<36O;F
M8G8[@#U"E'8`CP.->VA=@[KD?M_FK"5<AJ^KB3!=&I);A<5&TN2Q&R_=`<RS
M>GL5S//PSB.C*FFDZ<B"`+$47('+B8HBQ+:,@V^&X>[_`%,I)T\FC(^D^RI)
M>XW`B&#&A3S(.7A2+]W>UV5<$91P'CFIN\<XXIN8%I]A+9URK%3<U3JQ9XQ'
MUH>K.FL1(QJ+$TT`!S=.%/31*H4XB5,BIPG;-M=O?VL]T\RR.A<`8XTU`?FQ
M!7'!*A[I/);M88Y&Q-+CJ<X:@`G*G^TS^[AIT(:WOJS)7$\0@:7D*J@_;U1]
M)F2Y>\B&[]PZD$8MSN4Y2G4.8`,(`80V'5+-H$[A"'-B7`.^8=#4V`2"$=UP
M>\\0$!Y(*C=Z`73LU?[CV+D[_;J98Z16^S67Z/-I2"UU?6N'EZLE#MH^OXZ]
MV^"M1F-X\71/0(JD+P0]3U`$X\@N-[MMLA-LRW:>X+9KACDIQU?F*KCR055[
M>V[%U<&1X,?=R3@F`'*E8[R]I[MU\#"],QE'U<]]S9<)F#9V"\,;'*U2H5JL
M0Z4G9[$[B*DFXL,S),B/VYFS-NDJ*Y05W#P&F]GL+>][EQ=&3Z>$`EK"T.<I
M1`78"IMY<20F-D8&J1R9*B!:TW4;M%DW*67,IXAR"A"6Z+J-7KUQI.8J=0[]
M0JW:&4D\-'SU=EHF\M$19V2#?K)<"-CG*HW`QC"(AOIS=;&RAB9>6/=9&]Q;
MVY'-<0G%6IGU%(@N9#<.MI2'%H!4#JB5V]I>RN>:%V"P;UQP-3J+.V;.-0OL
MLC9+U_<?XJFKU)6.,K//P@E.+F(C8U=911L8A3N7`HI%52Y[BG:=OVV2PGO;
MY\@[3@`&Z5<JX8TN[GFB?%'$`LCB#@J(%ILT5VI[ZV:P=G<5Q2/7:/M/4"+-
M.Y`R4\@+J:MWH'T`K:*Y786`+-JA79!_7V3ERZ75<+@CLB0$R\C'&Q?MVP1B
MV>'W#C<I@K`6$E%RQ2H\TU^TO;;F)SF-7$'U8$5)9U<RY,9YZ\X>S)/P*=9E
M\D46%M;V&0,<S1NI)H>H1Q'^HNY7+%R2(%=-2JG,L5NL0%/O`P:SU]!%:WTU
MK!)W8HWEH<B+_1E4BPNC>6D=R6ECGM)(/`@H?0H4=*8Y@[M;V%S=VBRKBQU+
M8=Q.UQ)D)["/\'7BMV8V6K5C-H\,=KD"OV!O.EAW;B8B54U2%015;MP.FHH0
M$E2":]GVO;+':F3%L\DDL:B2,CMM>3\KE&8J"^>_DW1\43V-M(2`A:IE!"J#
M^$C),>=2NA]`_P`-9G+"KJLZ**P/_:'_`%ZX2!G14<7Q6*KK]3@57,U.8^=.
MR8D49^F**B7_`#SO0)&Y)F-S/P``$1^X=O.K7>5^N"Y]IG]T5%M,(C_U'[:U
MUQ[%=JK?VYREU8P56L3,(NA4_'UQD\K7EO:)%.H1]NAG+DS.1@HN1:(3\Y,2
MY`)&H)';$(U0645$_'<DBWLML9M<>Y7SIM3]0:QB8D',DJ@3D,ZC3W<[KWZ&
MU;\0:KGG(`Y8<2O*E2Z>YUR[DZ=["XOSE'TI'(G7W(T13'TWCY"2;UBS15@J
M[&R1$L@C*/7RZ#XZ2YP72`Q01W*F8OJ%.(Q=QM88.S/;:A#-'J#3B053.E;?
M//*Z6&X(<^-Z*`BA.5%+-_8C.DIVCKW4?K;'4&.LZ>+ELNY(R;D=I,SD%4:Z
MM+JP<-#,*]!NXQ9U.2CXA#%%9?@9)4!*79)407:6]BVS=?;@9.T3I:UB*HQ*
MD\$Y"BYGO?J6V]HUB(KG/!1.B$8T[S$K3+C*HHM\VS%!GKRD^?%5D\;Q$Y!U
MUU$^J7\6HI&V"0E'J,L*6_N>"OH";;@4`U7326DDA^D#A%R<03ZQ4R%LK6K,
MX&3I@/52G:;IVD5R=$@@\93J0\3JE(T4$A"E-ZR)A.W4%3<H\@*;8-Q\<=;/
MRK.V2&7;90"#\2GER3VU&N2@"`DK6PFH]*\UQA)QZA%7[-+95-(?)E2E)[IH
M"AMC@=-0!$OG81$=0-ON)/+^[.LYAI@=D3P4J"G$)2WQ]YC0"A'W41(JU3];
M`T64NR#<12*@\:F,*9N9E#^C]R9@$Q1W$!$0#??;6CNMJVG=9.^"LZ*2T@**
MA-DDC)#`3PKUQD')W28"2?%=&:B8A5GJNQ$R)`'J`@BF8_J%W*<0+Q`2ARW^
MFF+J]LMBL'65J0)SD`5QYDTN-CYR0]0E>W(#Q&1DHVMQP")(TH@LBFGN4JQ@
M312(GL``)DTO&X>0$=1_+=N;:SGW6ZPDD<J].M=FFUM#&M<"#2TPL>2*BH^/
M((B#5JFF(F`"F,IMR5.8"B)0,=0PB.WC<=8Z[E-Q=R7!17N7[O94YORCPK:;
M`/U#3%=H:**&BBDHS/#9=G:4=AA&XU>B7S\S!N$+#<*ZK:8-.&;2**TZR7AD
M%VJKA:0C2G23,55(2&-N!RCL(/6TEC%<-DW!CI+<`J`=)Q"9TEX>1\!0^"TU
M*@=7LR+=O&':/,=PQ?(.*SB*6Q97XS&]4F*](3(RTC&NW,Y<5IA_*D=&1(S6
M]J1%;=`BI4O)2B(VEU?60V[]MV[O_3E^H]P@@%/P@?P14;L2NF9+*\.T$D(U
M,PF=>'Y++UU[9=8\L8_S%?(&`L<C1'-NHE<3D8XU_>6:`?I+TZ:I\`HJ,H\6
M:VQHBD*Z"1BI%%3D.P&US8F79O8[FW:2QKD<>`:?F!]'#C3\KHPQ)4TFCA\>
M^")O!W7*MFOBRDGF#*2ZN5<O3[UXZE9F2MML11=-H^5F7[AV\DUZQ`%:1PG%
M04S*-U#D`H''>-NMT+N^>^-NB!OPM:N0!]G-.M(MXNS%H4NQ)4]:Y=L\$YQS
M]`7_`!M!R>"G.*[O0$:XTBLCTZR2]BK-Q5=OE'UQ9RD1*M$#D;-/:^S1!,#I
M.DN9C"3<HO[3=V5E*)I^^)`56-P;JZ%<O&NSME>T",1GGK!(]A%.7PW1'>+\
M2XQQN_E@GGM!Q_4*8[FBI*($EG-9@(^&6D2(+*KJHINU&8G*4QSF*4P`(B/G
M5;<O;-=R7+00)'DIRQ^WGUIT?*`4P'#+T4U_K-UVS/@&_P"7/<W7'<UB7*>:
M,M9H<1+.OSC:ZQ\OD%^S6AXE*45?#$G81;2/*+D10`ZBQQ`@\0\VNXWMA>P0
MF.-[;R.)L9)/PHWCZ5-0XK:6*=\@>.V]^HA.B`#TXUO>UO7+(F8K+@?)>',B
M1.-LJ8)N%CEX*9L4*I8Z\[K]UKAZY;(UY"$V*Z>.VB2)$3F$@$2,L`&(<Q3E
M:VN]M;02Q7D;I()6@$-*'`JH-/S0]T`@I*TJTHJ'PI5<51?8QK9K@^S1:\6S
M55>,*\E2(*@5>?AI&%D&B+M*RNYR2FYB5"21EU!15;II\?;?>3<P;#IB[.V:
M0+`3!RE=9:<.")CZZ[&V4?XK@[T)C1"NW7RRVCN-@SL@UL,0VJN*,598H,K6
MG!)$TU*R>0W==7824>=(OXQ)M'DA#`MZH^H;F'$--QW)99/L](TO>'+Q"?TT
M/B#Y&2<6$GUA*26A]/[S2$>_AT['19*9[<6JU6"HS[QK9%)""CK#4Y*MQU;N
MY#.!;NHRJGD%#,OQY2CP75`^_P!A2OR[C!<R6KG-_P!L`"`<P"I\%RH9&6S2
M2:6`/(R!4IS4FG.=;\5RF#^O>&L.R<HQF)?&&,:A17TO')+IQTD^K4$TBEG[
M)%T!')&KA9N)R%4`#\1V'SJ!<.,UXZX;A&XE6]%P]/6NPQB&,1C($^TK3/WO
M4?/=\SKUQS;E:[X71LF#[%8I:P6W%](L%4N5]A)5I)LXRHO7LA*RZ`0+)J\*
MBY1.79=-182B0QPXW[MWVZUVV6QMA-HF0Z7D%K7`9M08KUZ4RZ"1\K7O=@PD
MX89\^8I>^KMI[.W25S=/]@*O$T.J%R5(PF#Z:6,(VM3>APRSQ(EDLLFWDY!G
M*)6=)=JHT`"H+HBBL"B8;DU57<=K%I%L_N*T$NR"D9)TKL+YG2.$OR\,$XT[
M?4.I-:V9;/7D1*-8UT#&1<QSYO'O1`P@S>KME$FCL0)N<0;KF*?QY\:,-37$
M`HX&@4UGI!UZM75_KW7L2W>TP]SM3&Q7BR3ED@FKQE&R;^Y6R6LRZR39^4CE
M-3U)(?4W``%3<0\#J;N%TV]NS<,;H:0`BKRIF"+LQZ%)Q)]=;3'N!)RG=J>P
M_8!Y.Q;R#S/2\+UB(@&Z#PLM"N,7L;0TD7$@X4#V2K:3//D,@5+[B\3\_(AI
M,ESW+.&T`01:L>>HK3A:WN%X`5$ZUI>K_7FVX.N?:&RV>R5VQM\[9TG,K5X8
MID_3F8.%DVY&C.NV"2?CO(&C$$">@1$`00YJ\=^8CI5W?1WD<,;`088])Y'%
M5%,PPNC?(XB,:W+\(()\5)Q\**F4NLN5U>TU:[2X+R97*C,+X]0Q?E*D7*OR
M4S6KS5XJ7>3T*Z*,1)1KE&?9NW@HI+J&`&R0;IB/-4BC]K=;?]$;+<6RENO4
MUS"%"A""'8>VG)&R.3M.#3Q4+2QIP/9G_DI8(A>_8K/GUR>;/6;BC2IMOCJ*
M*XF!6@DI2KJ3CN6D1CX,?06.1R3UEP!0"E#<!B`V3;D/:QWT@S:J./\`:`P7
MPIJ)ETR/3*]KY%.*($X84LM2;V5I5JVUN<A&RUO;P42A:96&9JQT/)6)%@W3
MFG\5'K*KK,8UY)%4401.<YDDC%*(B(;Z8<6EQ+0C5P'(<!4FO9-1+:;CG$<Z
M_P`I<NP&#^I-0/*:A?YE'_I#3UI=365TRYA.+3B.8Y48<:;O'R$S09IPW7((
M($$R:C10YRMWB(B(HJI*;<`$/ZBF`-_(@(?4->C3VUAYCLA)`0)!DX(K3Q!X
MFHA!MSJQ=JI4FF1:D^(11T!VK@W$ITUF1ES@<2^0!9)-0IR?ION`_P`M8^?R
M[N]M)H:W6Q,"TYT['('Y@"M)/Y%24:"RKB1D#J"4I7QRE1*FB`_<#=$`$0,(
M``;CML`^`W^EGMWEJ7O"?<'`L&.G,GH::-R04##7LH]45!P6?E2[K@)CM"F$
MXB(JE*(+;F`-R%*.Q?YZ9W[=06_MUF4@'S8#'IZ.-2@`0#2M:R@"!*[0T44-
M%%#113'^R'=1E@C*N-<&5;$EYS7EW)T1)6.'IU/>0L,+>OQOY(IWZTO8EVT8
M=51:(<_L\R^FFB8YS%`2`:XL=FDOK.2_=(R&SC=IU.3%V:`<<,:A7%Z89VP,
MC+W.RX#UFB&;Y1^JU=.Z@LI627QGD:"8*FN>/7\#,VA]5;(T`H2=)4L%1CY>
MLS5HBU3>FN@R<JE(J!B";D4P`Z_R[N>D2P,,MJ_%CP$#V\P,T7FE1CO-G&2R
MX)9<-*.8`7%KLT)`XC&B8^^1?XX;:_)D>9EH6;M50<15=AIF<P[.OKTT).DD
MI)JVJX2%75L(Q919K*N#M=D$%%2>H(&6)R['Y?WU"R&-[0X8\B/7SI$6_;7,
MU[NXF@*0X$$\,!1S6^6'HNW_`")%LO.TW$8PCGZC,U$O0/')9$R)/:,D!KW-
MP_C_`%P]VCX,AL;?^D=)?Y;WJ,`N@=CR2E'?-N8`7N<UIR):X`^"BBTX^7WI
M<,A78^%L.0[2-@E7$4=:O8RM+G\,=N@*YG4BQ=-64N[;G#P!8]L]7+L(F3*4
M!'3_`/Q3=C&Z1XC:UH7&1H)\,?7E31\P[>,A*<4P83]E;YM\LG1YP5LJ?)L\
MT;.GGL@>/<<WY!HBH`E!55=8:^8J;=OS#U#>>(:CGRWO#1J$)(\1AQKL>_[=
M*XMB+W.'`-<3ZO9XTEDC\S/6!*9@D8B"R4_J;RZ2=3GKS(U=]$0T0SCV3=XG
M8XMN5"2>6)L[(X`09%!M)IIB50Z`%.`ZEQ^4]P>QSP^/6&@AH<'%QY?U4YG"
MDGS%MXS$V:?(3CZ%I7F7RN=&WT).SI,N+MT(`\0DLP>TVX-)J26FCN2M204*
MM"ED)GT"M3G<F0(8C9,2F4$H')RA.\O[PTIV'^RG(-_VRX<6L>0X#B"*,=V^
M1WK;3NO]=[*M7MSN.-K7<W="A#5>J//SKBQ1ZLHA(MW$785H`&"3-6(6*)UU
M$_4,!03`XF#1;;!N%U>OV]&QW+&%Q#W!N`"Y\TIY^Z6[+3ZZ,220Z])TM)(*
MHJ<ES-([C7Y?.K5UN]II]K6LF*$HJ<:Q59F;S$R;9O8VBD.M*/Y*6;H1IAH_
MXU='VID)!0%%5S!Z8F`0$95SY6W2WABE9HF[C-1#'!Q;BF*&FF;U9J>[KC9P
M+A@?#.E;8?)!UPN.)\Z93Q1-2F1BX"I"EZMU92AIFJ2J\4))`S(&2]EC&;4P
M/S12Y2F#EP$GW`&X:@NV.]AN(H+AAB=*_2#@<:DQ[G:S,<Z`N<Y@5"".F9'W
MTWS%OS.=:;:A:%<E15BQ$:#9UM_#D652R&%K1L22BQFL8-&:2"C65AD@(9XW
M<$(*('$!-S(<@6-YY3W.U^*$&:(E%`1"."5%AWNV>3W@8V\"<03R""E<2^6?
MHRLU1>AE=ZFW5F@@Q]>E6Y!PBL://(@_79*Q!7Q(?TR>G[H$Q2!<03WY#MJ%
M_P`<WC\C,OSM]6=.G>=N_P`MY>>.D$IXX5T-/ENZ+N@0X90F4C+QKB2!-?'U
MW243%NJLF9@J7\&/"35!+U")>>29BFW\Z>B\L;S,2&1C#FYK1Z%(5.E)&\V?
M*7_L=]U+#%=]^L4O@>2[)(7MRVQ/&6M6C'EG]=GFDL]MY#M$R5Z)K:C`9N4D
MW!WI/3311,)P`YOZ2&$(1VG<!?C;>V3=$*@((`YD@U,CO;>6W^I8[]+U94W&
M1^5C%=@S+@C$V$*G,9<'+UB;0%@E.<Q3']!6<2(,U47,%.5DRLG(QC--P^=I
M&6;)H-FX@90#G*&K!WENYM[%][?O[!`5C2-7<&2@@X!<`OJJ+^ZV[Y610J\N
M*<DHWWGY$TXO+&9<88HZ_P"1,W(X!A'$KE6X5J=K%?@:\YC$%G4[%MQL;AL:
M6=PJ*?%0B!S+J*E4*FD8$C&%J'8EA@GO9VP]\_"TM)PX'#GUIQ^X-^H-M;M[
MDC0I0@)PXT7\=?+ST_MV/E+E;+3)8WG&,4RDIFC3,--2\RW/(2SB-;,85W%1
M1F-J=II)D<.`9"<&R*G)00*4P@NY\L;M!*61QF2%<'A`#Z%44U'O%DXD.<6N
M`XKS3#G6]<?+CT2068I$RS(O`?,&;\%6-"NSI%J+M(5!9/CIP8BVD68AQ71$
M!%,X@&XZY%Y8WF4D-B#4_,X-^TTB;?=M@`=(\H>E>H?EFZ+@6*/_`,V9$Q93
M?U!+0+X8L/\`O+($_.G_`+>].-]51'[-Q,!BG*/T'33O+N[A0824\/93C=YL
M'8N<Y@(S<T@'PP]-(H;YJ>MJTQ34V=)RLA4Y^RV.`L5OGJ^6,;UEK`Q[9TE-
ML&,:>>_NYJ^=.BMU&[-<KUF?8RZ12F()I1\K7PC+S)&7@!&M<"23P/Y3XTV=
M\L>V)?C#2XC%KAEQ"C&E^=_*CT>9.XIJIF$%B2]?9V%!^TJML>1[<C]@O(-8
M>0<MH=0&%A,BW$AV:H%516$$U.!AVU#_`&#=^,#Q3HWC;S\L@/@#1?'Y;NDR
M1()=[>+A&LK&NLC%R,AC.[-V"J;=S[-=Z*_X@XBQ2=%,F*A0,'(A@_W1U)_X
MMO*`MC#@>3@?L.'IIB7?]OA`,ID:">+31;>?*AT`O"T9$R61)MHX?3D="1SN
M1H=OBBM5)1R9L$J>3<116C.":*D#W;A4X)HD$!,&VX@[9[;Y@VR7N6K"#Q'`
M]"*>.\;<@<Z0(<J7?KY8\4=DJQ,9$Q-;;1-4UI9IJI(RLS5)&OH24C`BV2?.
M(-272;'EXE!984?<I)@F94AR;@8A@U:7OF7<K%XM[FW@;*@)`.(7FE<MNU>L
M,L+W.B4H404Z&'H$)%E-ZQ32!S<?+@`*F02B(\B)IB&QS>.6XB'CP`:SNX;[
M?WSP]I$8'`??5H&M&%'D`````````V``\``!^@?RU3]3G7:SHHH:**&BBAHH
MI@?93KMUKS#GG%EBN&9GF+.QD!`*,<>-JIE6(J%\F:P+J<<'_$U5XZ&5DD".
MEWX>[9H@?B"R9C&*38EWMNX7UC:O#(&3V#G8ZV%S`Y.80*F>.50[NWAN`ULC
MW,<#AI=I)IA5FZ!_'&NG+M)SNBDRD5'MC9R#R7[!8M6DD,E*LF;:T3L@,NJJ
MHI9B.$_6>M%OO`RA05#8I=:.#?\`S2U@,-HXQ)\*0NTIP3!$2J6?:MK<XA]P
M0]<5D"^E2M;*/Z-]"W%N9>S[J5T^25T<7A2'-?RGAN-N44%/QL>J1@P+6,5]
M]()6^/<-Y98/3.*ZZ*2A#"D(@*&;YYF8&]RT>Y@80%B>A5Q*Y>BGY;':Y0]I
MF:TNC#5:]H+4_$,<S13MG07XTI&&FXEIW8KM;=*.GAY26<YTPS+2*4T<S#W#
MB65FE%5%%DDT#%,W.9-/]X#&*)B@(O0^8/-,;B6V;C_]+S[J9EVG;3&UK[EP
M`XF0%<.II0&?1[HW*SDQ_;G="-:9,G;K+6&H2]*RKB"+L%4=.:;&QLU7:Y`0
MG%%VR+6&`+&3.B91!LLH?P4XFTD>8?,S0W79JP,3&!V/Q*OR^BIKK/;906LD
MTG4"2UX!72`A3IC16L_1GXXIBN8MC?\`]ETF#D:766M?B["WS#AS>XN(^\S,
M_(6.5CG+T8V3FY&8D%V+LZ0<#%1*F)0.F(:C?O>_:;@&S<DKU=^F[X,`$&&'
M/&F!8[9W(2)F:HP0/B:KL<SCB:X9#Z`=$[/#*/3][$ZE0WN3[Y,-8]MF##P4
MQMDJ9+&O+.PBO>G+&-K'%0AXQ!=LD(.4F2;?U"@!BB+[?,6^!R&P!N`QH)[3
ME+1DH3V\:3/M=C+\8N7LC).`>W2O%%4+[:1C/G17K.[2:.L(=T,*N,H.6>.F
M3!O=LQ8N@CQM1J>-%(-HK5DJVY0<+O[B";!^LLY*HF=$#&3.!#?<[8;Q?F8F
M^MIA%B?@C<2I/'#(8TQ<65GH:+::'Z@9$N:,4Z9FGA8KZMX`_P#YRT_"><.Q
MN,'=(0R.]L2V7,?9*JD?2$,A+W>5DX>`CKI(O/PTU*QLDZ]LHF<4UG#Q,0],
M!+L-1+NMW'YBDN[.V>Y^@C0]CB=)"$EJ*.?(5;V\$++$Q7#VOA/S$%!PXC+&
MDQMO07I$5]9H[+/>L9&P'RXE:\B.[GEG#<7<7=@2J80[NGV-^[(A(QKES$#[
MDY3D(\+X4`-@`=3K7?\`?FR&2SL@AC`1L3B$!S0#GQJ+]#9QVS623+#J):7.
M!'@"3P%+YC3JITX@L&=CZ+C?L_!2-)R%B&'J.0KI&Y"Q3,IX[I[-K9$V%J>R
M\<D#"/2=-Y!R(.9-06QRMQ$/(*&U67NY;M/=P23V[F7#)"6#0X%SBF`!"E.0
MKEI86<+9>U,7![4/Q`Z0N>>%%F\=6OCHN&+,"X\E.QF+:_.8RJ47$TK)M9RC
MA^MW.^QB$`UBQDYQ5JJ5E;$W[1L#DBA""5-0QCIF`IS@:?8[KYKM)YYFP32B
M212UT3W!KN0PP//I2S:;6ZV9$7M#&N.(>`IXJ>--OMG0?XLK`JB$+W5Q]3B-
M*A$UI).(SGA%XX5FH]RZ</[G(N9=X]6>STT9YQ7(/%LF5-(J29"D`NG(M_\`
M,,;WF:R#PYRH8GA.@0"F&V>TK^G+'Z'-]J&C]:.DWQFV*&N:-4[=T*D14\S@
M6]D/7\S82DHZ.<13!-D5\FI,?D!A594B"BRQ"JIIG654,`?0"O,\P^98I=5Q
M9%]QH/S0N721R3(#CRXTZVQVYQPEX?A>GV&GO90P1U5M_4#&6';[F&OPV)*X
M&+(ZDY::Y`I]4-,VVJQ31E3YII9TUV]9E[%9&B!E/33`_NQ6$Z1>0$,7-[;>
M[K:[L;NSB,EV6N!9H+D:?ZJ*$]E3Y&63K7MREG81%4`99KSI#NO'3_IOC?/&
M++UC3M/_`'W<ZLYRD6J4);+6.;.:R6R<8/&>1)))C%E&R2+^)C%Q%^U14.1N
MHD"RQ2FYB:?NFZ[Y=;7);36YBM7:-3^VX``'!20@!.6(4X5!MK&QBG9)#+J>
M,@7@KX"MM>^GW3K(>7.PMRA.RLG0[;:F:J6>*EC;.-<@F\!,(("U<S%RB&+T
M9&#.+@B2SEI)"#-5<AA43V54`46F[[A;6L4#K5LC`?@<Z,D]`TIER2F[G;["
MXNG2=_MS)\0:X`^G%<Z;0VZ*?&T@]I:UD[GU":6B,?4NM4=)?-&&(<RB,%8W
M\K'VUD6/6;_G7,Z99TS/S!=HHGOP+S(`A9,WKS('$Q6DFHG'])Y]V%*=8V;6
M1">8%C6(W41B%50IQY5JK]T*^.VTSL8]?=[*K6WC""8Q/LV&5.O<>L^]K*2K
ML99X7VB)UI!V]D#)G4`H%$$"$``X;:<MM^\QQ.<8K-SG'-8G'W85'EVS;'`?
MZ@M_MCV8UOJ[T3^,I"(8D+V_K$O#5YI!-K^,9G[%45'7!)I8YV3AU+P>$>)(
MMEG4C*(MBJ%%$ZA6"94Q*H94Q@[[YJUJ+1_>+E9^B[`IP&G'PIX6&UD`/E"#
MD\#UXT8$.BG0]LI1IV&[H)-L8(%S`SQO3ELSXHF:+^3L%;?0N2WM3DI(7*KN
M5@T)!-Y(BV7.9!=NB=R``7RQ-O\`O,K"PV+&RZV%Y;&\$D'\2\RN'/`4.V_;
MF`&296'+6\$>A3GX46JQT6^.&(@EF-8[JU=5Z:+:,YF<',.!YPSET2.FFAI,
M[!ZU>QD<HYBWCO8B9"D)P,J38Z8')8'S)YJ)QL2G#]!_W4@;;M9RG/HD%$W(
M?13XYDJ37%J+W#QBA>J?CV(0JQ[SGO$,A3\@N(2/=EJ![JS<&<)MZG-SB8F=
MJ122(G3,MZ0B;QI-IOWFCM]F6TF-F7G6YD+U`)Y@<."TOZ/;1_FL7JX'[339
MI'HEUYC>O%)0C>W?4A_V'EH5Q$6]6V=A:4^QO$(2EC!^M+XP>IOH]^V7KX,C
MH)J+-%S+)+NB"`*B!M3K#?;YUPYM]:7+;4`EICA<7$C(.PR/&JZ3;]N&-G-`
M9/Q*]ON7C5C;J72L<XYZY8BHV*K75KU2ZO3V,.QN5,EV<[7+1)M3JA99V.E&
M$A*MG!9.RB[5.!7"OI*&%,1W)L'G&X2S3W\LT[2R5SE+2"".00XBM-91MBM6
=QL<','$8@^D4XO42I-#110T44-%%#110T45__]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g234488g47v78.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g234488g47v78.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`/`![`P$1``(1`0,1`?_$`*X```(!!`,!````````
M```````(!P$#!@D"!`4*`0$``@,!`0``````````````!08!`P0"!Q````8!
M`@,%!08#!@<``````0(#!`4&!P`1$A,((3$B%!5!46$6%Y&A,D(C&(%B"7$S
M)$0E)K'1X30U.!D1``$"!`0$`P8#!0D```````$"`P`1!`4A,4$246$3!B(R
M%'&!D:$C%?!"4K'!<C-3T?&"0Z,D-18'_]H`#`,!``(1`Q$`/P#[^-(0:0B@
MCMWZP2`0#F82G"?WSJO;FMLGBC`-+D,ZY7CRG1E$HA^C$XRI#OA4`29"R.=)
MW'1+AH8"F58-4W;\>("<LIA#5AINWG%4OW&[.II*!)U_F+&@2G/$8SPC@K*U
M5.L4[3974+R_2.:CI&/O.G[J2R)P3U]ZJ[=CJ66(W.E4,'Q$)$U*%V`BRC<9
M"QL).<L"Q5MR&76,D50@#LF`&V#O;OG;E%].AMJ*A@_GJ%DK/,!$DI!S&9EA
M'/1T]W"":ZH07"9C:C`#ACG*.?2UD/(K?)F?>FW+5P6R';,,2%.L%<R`[CXV
M*D[7CS(T.M(0QIF.AV[:.:RL')QKIJH)"ASB@4W:.^N?N"DHUL4UZMK70I*E
M*@6YE02M!D9$XD'2<2+2YDME04L<I?&'>U6(W0:0@TA!I"#2$&D(-(0:0@TA
M!I"#2$4$0`!$1``#<1$>P``.T1$?8`!K$\0-3"%=3N;GJ+<6>L4!_*0^+8>3
M>UJS9+CSBS<6Z3C7)V<[7,>N5$%2NX9!0BC5],)"4H*@*;8YS%.8+(FE:L+;
M-96['+JL%:&<PV/RJ=YGS)3PSC45(J&OI*(4%D'3+/YQ.%%QY2L:0*=;HU;B
MJU#E75>+-8QJFW\Y(..$7<D_5*7FOI%V8@&575$RB@]XZAJZNJKF_P"IKEEQ
MWGD.0&0`TCVE(2G;&8'."91,(E`I0$3"8P%*4I0$1,)A[``H!V^X-<DP)#4F
M0'.,F0!/`0@G2&FEDS+W5%U1,'0.JIDJXPF-L<KIHI)HR52PVP6K4C/I+)F,
M=TWEK:H^*@<P`');@8NX'U<NXW126NW]OR'68;4XYR4Z=P2>828A+8!55C]S
MG-)DV@?I`\T]"2H3'`80_P!JG3EG$Y!I"#2$&D(-(0:0@TA!I"#2$&D(-(0F
MN6[^\RKE%+I5H#N9:CZ6VL>=[S`JJ-2T6D.5=V5-:S"!O\%<\@E3,B0A=U6L
M>*BPE\11"PT%(BVV\]PW"03N(ITK'G7.17+5"#KQD(YW%*<>Z""4D)W$C/V0
MQ5#^G\"T/C2@)Q$:QQRSC80]<AD^!I76YFP*L8_P`9,JWE]CG*)S*@)P,IXC
M;C"/-UZMM=6H4#4;E!2LU2,B1KM.FG"/:%ME1;205IS_`![<^<2!K3&V$$ZO
M,CV.[RD-T>8;?R*.3<MHIIY$MD$158V$\/.15"=N<PX1\#"4L;=$\?$)*&(9
M954YP["!O<.UZ%BDGW1=DSM].3TDF7UG9':D3_2<2<I"(.\N+?0+;33*W"-Y
M&!0B>*O9I[X<G'U%J^,:56,?TR*:0M7J4*Q@X6-9-TFZ*#)@@1$IA31(F0[A
MP<!56/MQ*K',<PB8PCJJ5-74UU2[6UB@I]QQ2B92S.7NRY9")=EIMEM+;0D@
M)`^`_;"KYBZX<>XMOU4Q['UNS9`>SF2JKBN>G*J5FI6Z7<;<[1;QT%-2CE9-
M-S.(-W!'*[)MS%D6X[GV-X-6NT]D5EWMK]T>=;9IV6RM*5>=82)E0&B=-QUB
M*N%X;I5AJG`<<W`''`3PE/CK+A#LAW!_8&J8A0*1($"434I177N$&D(-(0:0
M@TA!I"#2$&D(C/,E^^E^,;I>4FAY&0@H1TI!1")>-Q.69X`,*Q!-4MP%5S-3
M[ILV(4.T3*ZZ:*G]55MLJP:*IJ/!(Q/RC34/"G:+I$P",/:90F"->7Z)>E2]
MW%ZNK:^H+)3Y*6M$ZHMYV0O74#DARA"031L*YAXH>'FY-)%JW+^FBP:F$``N
M^K2PEONGN%FA2-MDIP2F>/3:;\1*N:I`>T@9Q$U26[52OU()4^ZO4SF3@`.0
MSERAI^F_$/T/PY2Z"[?N)NQLX[U.[V1\X,]DK/>YPXREMGI!\<.:\5>S#A0$
MS&_"@1,@;%*`!"7ZYKN]W?KA(4ZE2;2!()0G!(`R`VRPXQVVVC%#2)9Q*\5*
M)Q)4HS/P.$8KU&=1T?AAA%5JM0SG(&:;RL2-QSC&$.5:7DW+E8686*8(0#C$
MU&&6'FNW:O"42)F(01-OP[['8G;KNK7B6[,P07G98`3E(<5$X"6N<>+C7^D`
M::&^L<,DIY\3P',Q%>+<4S'350+9+HJ,<G=469)%6XY!LTJ\!BT?3SY<5%SN
M'G"H2%QAC4D@J5HB0J1#()\!=EEMPD*ZN;O]Q::6>AVQ32;0`,0D&1)`Q4XX
M1AF03PC73TAHJ)RI6!ZTI*E8Y$XD3X`SY0G/1`ZSU=\>9`>OLEVJQY(ZC\C6
M6SV7)K\'"-5Q;B^JOE:O'R%(K;X!2@9.Z-6R_I;4@)H@CP.S"4R>PVKNREM%
M(\Q5M-%%JIVDI:;(^J^YP5R09;E',S&L5WMNZ_<'ZFG=4_O6HDE0`2D)$O"1
MF">,1NZLMAS+U40.`NDJH0LMC+I336?L[U-J)O*FQS<^;JLI3*5M?G1![<I&
M&0>K(-D044,^D"G6XP+PB6898:LMFJ+WW<M:*ZY-;4M)$B6\TM@#R)(D<A*6
M/&.*KI/N[[5%:72VA@[_``C`JW`J69Z$S$N<H8W'V6<JX'ZH\R0V;^H>;RIB
M&B84J4Y>Y::JT+$1\+F"YV=V:G4K&4!5&BCYS*R=;:.S+,!%9=0!;[!OL.J1
M56VAN=JI'+-2ABJ=>*0DK)5L`/B63@D3EC$U;JNOI[F]1W%]+J$MJ7.6V6,P
MD#4@82C9;BW*U(S)5$;G0989:%4?2$4X%9JY8/XZ7B7`M9.)E(YZFB[CY)@O
MX545"@<@B&^JK<[976>L-#7H*'0D'B"#B"#J",08L%%6L5].*A@G:0,")$83
MD1$C:X(ZX-(0:0@TA!I"#2$&D(6&S6%KDO/4'B-HQE%(W$"4)EF^RID01A3S
M4@E(M<;U<%50_P!1<F6!S++D(`E0%HW$1XC!PR3+;M';36+(*J@J;1I(`@E7
M,9)'.?"(MU\/W$4`29-I#A5I.<MLN.,_=$/Y*9K9OZT<48Z*;FTSIKA#YJNZ
M!@(*#V]V5!W"8VCS\0J\X\:V!P^$HD+P@("!AW[+-:MMD[(K+DK_`)2X+##7
M#8#-Q1&<O#M]I$:JEA%=<4MJP33D*]I.43)G_J#'%XPU#H4";(6=KV`-:!CY
MLH=-(@+F5:FN5O>$``AZ)7ER\Y^OQ`J=(@D2`3B&T%9[&JX,JN%6HT]F8(ZC
MA&`X(`U4K)/QCIK:[TZTL,@+J5&4I^48^(\M/?&+8LZ>YO$T'<,I2Z[/,_5-
M;89\^F;E8%R1<>XEUFQ%F5#J2QVYS4_&D:_2*1LW(4RA4^)0XF.80UON-Z%<
MX+=3;F.W4+&UL>8@9J<.2EG/'(_&-::5QAM=3+JW`I(GEA.>T<AQA.>L.ZW_
M``_BI'!U-D)Z^]8G5Z[6@RS-?;J@-7A)%\FSEG;`.:"$'5ZM%/#QC!38#'X>
M>L`F*80N?:=MH;W=OO%5M8[1M4U'<1XE)22#S4H@$C2>$1-RNJ*9IFVO3^YU
M:);>!U_LC$\CR-RQS2ZC_3EZ;W2,WU$Y`IJ!\M9)8JBWK^(Z@\;HLY637*4Q
M738RL4`MHQF!B*)LS"J&ZIR[S#:VNX[B]_Z%W*"UV_3&5.U*744,$X:XXDC-
M7LB(66K'3,6"C*EW!]9"MLMY*YJ5+=HD3(QP`ACY$*'_`$]\#TS#&$H%M;LQ
M7`C>#H\,_,9-_=K;Y=NTE;]>Y%JF=PTK4"@4SERL?8"HH@B0W&(FU5&DW/ON
M\.7*XJ4BSL$!:L2&D3\*$S_,K+GGE(1(//VSL^WBGWGKN$[9XK),\<-,#+2/
M)Z4>FI9[8"9,O]@?W1*"LCVTL'4B`>1O&9WR"3"V9>$H"!W3"-9I$BX!)4!(
MV3(NJ7M.4P[^\;TQ2D66V-H1-E*5J`DI"!(I;.."B)%4H6*E>KU"[U((63A/
M,@XX^Z,\Z,UEE\P==PLRO$JNAU+K,XA)<Q1:A--JA"!<%6`)H($316F3[F+L
M8P'`1,8PCN,1W0XZY:[.:@@OBB4.80%#9/4^'&9CKL1'W&X)3+:'Q(<,#&P#
M5-BS0:0@TA!I"#2$8#>,EU''R+'Y@D1"2EG!6D%7V"0OK#/O#G`@-H>(1'S3
MPQ1'<Y]@33*`B8Q0#?79;Z"IN95Z4?21/<M6"4@9DD_WQI?>0PG<O,X`:D\!
M'I^OR_#O\IR_%\N^M<'F(W_O^=P?+F_FMO5>5X]_[C;LX]]>/3M_UD?S=FN7
M]3+R_/E&.JY^@_R]WO\`T^V(!KYKOBK(N5)&S59>:H%ULDK?E<GM9^$394BM
M0E/CD2PE@AI%XTFA29*Q"PHBR272V7$YA`>,=3%>Y276VT+%.Z$UM.@-=$I,
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M\H`S&IQB?':_E6KASRSJ@W067%)(.)10$4S*"1,OYCGX=@#VCJ%0WU5I:!`W
M*`F<A,RF8DE*VB9R`,:(X[,-BH;O+?7QE:`L"^7<HSLC@?HPP-.$%I-O80DB
MDTB"L((I3N^*7?%2>2+A%,`(BF<QA'FIF'[!54-'4)I.Q+>IMNVM#JUCP5X2
M0"<%##'0'+`:12D);0^[W-6`J>$DMIVS*9B4AKKC\8??HZZ5GN`:W;,E9'=C
M>^I#+JR]JRO;C*IKKK2"PJ/&M4A%U"H)-XN-YG*`"\"9U`#N(4FU/[N[E3W`
MMJU4:13=O4VQMI`.$@0%.*(S*I3'`&42]JM(HRJYO`NW-T%2N..*4HGY2!@>
M)B!<!X?S%GEY?,A9_IMQQ;;[G;#DE)F2DVH2B&*XUVZ;QV'*%!K`Z6IM<=@S
M16EGH&,K)>96X#^(I@L=WNMJ[>I44%DJ&ZEL->%*1X0ZHS+SBOSD)FE*,-I,
M](X*2V+N-:[75R#,N8%6:0,.F$D9:E6LHVML6+.*9,XZ/;(LV+%N@S:-4"`1
M%NV03*DBBD4.XB:9```^&OECBW'7"ZLDN*,U$YGV\8MJ$H;3L0)(&0$)5T*L
MVZ55S[()+<YS,=6G4"]D1$P"JF]3MI6(HK;`'"HB@T('"/:4NP#JV=XNARLH
MT@22FW4X_P!,3B#L5&W3FJ?29J>J%*/*6$H>+51B>@TA!I"++AP@T05<N5DF
M[=!,ZJRZZA$D44R`)CJ*JJ"4B:92AN(B(``:R@%:PV@$K)D`!,_*,*4$)*U&
M21"3S/55-Y-F7=&Z3:JGDZ5:R*L/8,LS*;UAA2CNVRPDD474X0B3NVS+1-)0
MI6D:"A`7`I5%0`=69OM]NWMBJ[C<-.")I9`FZOA_""-3$.+NU5J+%L^HY+S2
M.U)RQXR.D2=AWIWC<?23B^WBQ2.5\S3"(DF<DV@I#N&3<Y.6$%3(H-V=1K2"
M/A!NV#C5'B.J<YC#KCNEZ<KDBCI4"GM*/(TGCJ5G`J)/&.JFHBVH/U1ZE9*6
M[(`9R`R`GD<X8_8/=[-OX>[4)$A,PAO]1BT/XWIU1Q_#O7\3,=065\3]/;&5
MCDE55XUKE&Y1T98G9P1$JJ3<:FW?IJ*!^`%-_AJ?[94RS=DUCXFEAM:QEF$D
M)SYD1&70@TP9*@E+KB4F9E,9D`\Y0\D7&,86,CH>,;D:1L4Q:1L>U2#9)LR8
MMTVK1NF'L(B@D4H?`-0;BU.NJ><,W%J))XDXDQ()2E"0A`D@"0$=[?X#]FO$
M>HH)@]H&^P=)0,M<HB>TX6QI>,@X[R=9JNSEKIB?UL^/Y5PLZX*XM84$&TJY
M:L4UR,3NG"+9,`4.F8Z?"`E$!V'7:S7U=/3NTK2Y,/2WC4RY\(XUTJ'7DN+E
MX#,`93GF8ED`[``?=L/N[MM<(2$@)&0RCLCB(@40[.T>P.[_`)ZS+&>L)">D
MXJ(B'Y1'M]FWV]^LQ@F0R)C6]T@6N.Q3F;J?Z8;S(M8F^O<Y7K.F/&[]9)H-
M[QKE9RPFFS^"45,!)1]7Y(RC5ZB0QEDC;>'A*80L-]<37-4MQ:,VQ3H:4/TJ
M;2!+W@3!UB!M[[%%6N6IYQ)K%J4ZE,P/`I6`Q.8PP$;(`,/M((?Q`?\`@.J]
M*)X&9E*4="6F(J"8.)6;DH^'C&A.8ZD95\UCF#9,.\[AX\51;HD#WF,`:2C#
MBT-)*W%`(&9)`'Q.$(C<OZ@N,'ET=8?Z=XV2ZD,RI@;>`H1RFI,01,R`.GED
MR.8BE=:-&:2X'.#8[I40`0X0V$0E[?:&JPAVMJ$4U&G$DXJ5R2G4Z^Z(:HOM
M&'O1T1%16J&`;(4!_$09`<8ZS/IIS5GIT26ZO,@M%:>+M1XQZ?L6&=0U)2;J
M%,5)G<;8FLE8+B=%-42G*!T$%#``@'#N75E<[AL=A8-)VFP36+'U*IT`JF,N
MFD@[-"8XDVZYW,`WA10PE4^FB7BS&)!\LM,\H>FL5>NTZ$85NJP,77("+1!"
M/B(9DWCX]HD':)46K4A$RB<>TQMN(QAW$1$=]4=^HK*Q]557N%VI43-1G/Y_
MNBQLM-,H#3"`AM(D`)>R/>$1#?8N^WLW`/X![.[6J-D4X^W;A'W=X?BX>+A[
M^_;690G^S\#VQY[[TWA9>J^G[>;;^2]1\O\`^0V-Y?ROF/\`.]_!P>/OVU@;
MYF7RG&L[9#J[<\)RSY1Z0;[=O?K&/*-V$^44\7P^_6#NTE##G!XOY?OT\?*'
MAYQ:+^,VWXM_%OQ;;;CW;]FO>F,H\C;/#=%WQ_R_?KP=WY91Z\/.#Q?R_?K'
MU.4_?#P\XIX_AW^W_IKW[88<_E&OSKS_`&8_+56_=)Q_,_JR'TN^0O7?KGZW
MNMR_I]\E_P"\>7OQ\WA_P._][V[:[J3U$STMO3UW>7YZQ`W?_KO79^[]+U4_
MI[O/_AV^*7LPC6JG]6O.+_)W_P!:_E3DF\KZC\@<OR_D_P#->K?ZQQ<7#RN/
MQ<7=J>3Z?8F7H.I(3G/W\IQHHNMZES9ZCHR,MWEE/"4\<N.,LXX47]D7F&/[
MT?WG^L?,"G_N1\Y?3KU+EARN?\K?[.Y'-_#YKP\>W%V;ZX*CU>P]/TTMQELV
M\^.D:+A]AVG[[+H[O\R>V?X]T;M>GO\`;?\`)#/]LGTG^1=OT_I5\O\`IW%Q
MJ;^?]%_6\SQ\6_F/U=0KGJ-_^XS_`!EI\(F+3]E],/LW1]/+#I[?G+'XQ/VO
M$2<6_P!3M[OA[^_[.[6<)\HR=LM8Y&_+O[P[O?V_=I&,(M_I\?Y./G?#?F<G
-[>/D_=\-8C&'OC__V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g234488g56x52.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g234488g56x52.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`/P!_`P$1``(1`0,1`?_$`)L``0`!!`,!`0``````
M```````)`04'"`($!@,*`0$``P$``````````````````0($`Q````8!`P$%
M!0<#!0```````0(#!`4&!P`1"!(A,4$3"5%AL105@9&AT2(R%O#A(W'!DB47
M$0`"`@$#``<$"04``````````1$"`R$Q$D%187$B$P3PD:&QP>'Q,E)B,U,4
M@4*20V/_V@`,`P$``A$#$0`_`/W\:`:`:`:`TIRYRJFB79[@[C)2VN:\WLR"
M%G.K)?3\98A1616%O(Y-M"'44KP5DP`D.T/\^KV@(IFZ0,+<75KFG'T'@6O%
M#E%=TD9K+W-W)D-873U)^]K>"X>!HU(B$DVB9$H:)4>LWDV_0:O`,H+ER(*+
MAT@<FX"(CI?+CK:,=/#U^S/6X;R%EG$N867&#D-:T<A*W"OS5GX]9G^CHPTE
MD"(IJ4:%UHU^9L.F*;Y(JS620?)+-R$2E8P55]@515+H4LN7BHHJMS>?0H-`
M-`-`-`-`-`-`-`-`-`-`W"E[&@G(O+%ZR7DQMPZX]3CBO7J0BXVQYRRNQ(U<
M!A3%LFJ9([>+*J)@-DNYM1\N+3$"F:H*?,[@/2HD-"PNF+^1D35']WHE_:;/
MX3P?CCC[0XW'F,H,L1",A,Y>O'*QW\]8Y=8"B^L-GFG'4]G)Z14+U*N%C"/<
M4@%3*4@#C:UK.;;F6CG*F0QSB!2$*8YC#W%*4!$PC[@`-"N^A$/F7EYQ8SE=
M>%%PQ;FNARCZG\JW[Y](R$NK4W$!36.(<OP%[>RZ5D;Q+B/A9!-VU21.Y*D@
M^,LB*1C[E$!IIBR*MM)4$ML=(Q\NQ:R<2_9R<:^03<LI"/=(/6+QLJ4#).&K
MML=5NX04*.Y3D,8HAW#H9FFG#T9W=`-`-`-`-`-`-`-`-`-`8>S_`)EK7'W#
MF0<PVQ3IB*/7UY(&X`<RDG+.%4HVOPB!4P$XN9R>>-FB?@4RP"(@`"(.TMCJ
M\E^"3>DONZ?@C!/!'"D]BS#"5OR447>>,Z2!LMYMFW!EEGR]JLY1?LJX*SD3
M+IQE,BG2;!JV#I3;]"@%*'4.ATSY/,BM9\NJT1G7$V;:EF![E*+KQ7+.6Q%E
M&S8JM<3)+,`DT9>N`T53E@9-7;EPWA9YF]3<,%%RIG70'J`H!H<G5J)6YZG(
M&3,>XK@EK+DBYUNE020]'U"QRS.,2<+F`WELV*;E4B\E(.!#I2;-R*KK'$"D
M(8P@&@2;:2W(//1JX\1%KQ:KFNY5V#>TV-L><:7A^M2\8VE3OF=OR2,M?LAV
M5&49&_[B3)`1E>C43%`[*)B5=P*9ZJ4".^6]JVXU;1(1>:/&<6LHXPR9A^.)
M6L?98R=4,.9EQ7$"E'455UD-ZK!TC*M:@2`6/K=Q@;>JQ8/P9$00E8M^<5B&
M7;('T)5[^HJZ7UM5-I].BV-]-#,-`-`-`-`-`-`-`-`-`1K<T3(Y9Y"<-.*B
MI/F(.V7V;SODABN=1-A)4O![%*3BX5X0I@*_2E[9)-Q%N("7=L!S?M#0T8O!
M2V7H:=?>OD24^[0SFLV3.'?'++EQ+D*ZXX;JWH6Z3-U;JW8+71K#*,T&JS)!
MM-2U(G:\]F$T6BXID%R=0Y$RE*4P%*``);;B>@L0<7^.V&8.T9$J.*Z^%PJ]
M0L$C&6^R*35[ML::,AW;I,\=9;F_LMA8J!Y`!NW6*H(=@;[[:%L2G)5?F7S,
M*^DA&-X?TZN-!B=)!DZK8K&]4%8JQ1>3]ZM4P\5,Z,/4X`570CYAQ$Y@[3#O
MH7S_`*UEVG<L6?,1<M;EQVH^"K[#9%B(_.3S(^0W\"=T0*[`<?&!YM/ZBU?-
MV;Y%.3RE-U=NT6%(6[U%14Z)U"$.8HFBOB5G;=UCWZ$BFX:&=M+<:$GS.JDF
M9,IU$R&5,)$BG.4IE#@4QQ*F`B`G,!"".P=NP"/AH#Z:`:`:`:`:`:`:`C2?
MD3D/5P@BO]U/X[P1?OZ^150I2-G4OFIS'R[EHD;8RBB[1!--4Y=]@`H#X:&K
M;T+?_3Z"2W<`T,C:6Y3</;J89'*O68GSU+IP."\T3JCCY5.%Q/D664==)C_+
M$C:?,/#N.@FYS^25'JV#M';LU!VP>++1+\2^9#C!9;F,">D?PZQM6%)<N6N1
M5'QWANALJ:V;2]O3-D-!S+W6PU&(.NB1Y-P5+<O%&7ZP0:R2S4RQRHE.8*W3
M=&J_>AP:.-'ZJ]LD^767[C4GCM%7EKRXY-<1<;J-L87'*4_Q^I5RE\<.'0%P
M-Q_P?C`DMD*"K]MC2-72UM=$F(BI&F`.F$E/NWD@((B9(NE\M*\,?]_'7ODT
M>JK2F&OJ?]373UF4&_+?--#P5GSBGB"YVR:S%B#,'+!W#Y0F%0L+W%W%'CT]
M7GDY^QS4R244<3DL\;*5.$!V559TL(K?L3+O8IBQXJYJ9<RG#:LQ\#-63_5P
MG*_@C`SK%<%!7G-=BI/'ZV9SD)1B[_@F,$LI)U\A8.1"+?,SFO5U=O5DHV.1
M6.+(-SK$$2@D(X/#RO:R^Y+@M?.#D(]O/J(\$,:XND'3F'PSR.AJO?[1#N2#
M&%R7?&C)Q,XW<.T78)O7D'BF+D%99L4O4V"1*DH/F?X]"M:)4;M$P3[;@/B'
M8.W?X^S_`%T,\H;A[0T(E%="1H!N&^V_;[/'0&AU[]1/`U4L<C3:K#9AS-;8
MB9DJY,0F(,36VS!#S\4Y>,GD3)3#YG#023I)XQ4(()N5=M@-^TQ1$=J^FS6J
M[Z<5UM(\"PY:\R<F'.GB3@=9:LS3)YIK#R'O[/'+8Q>@#`FA`,H>0E'2H]0=
MI5O+[!#JW#M$UIB7ZEX[E)HUR9LW.G"^8<9<],B8ZXY5Z+Q[`OL!6AY7;;>;
M+"P])RG/QQF]LO;;Z>UDF\!4+6"*JJK$3+AY@`*9B''0[XZX\L^GPMM0[:Z;
M?4C?.,3]2>Z0<58*OESA6:$FFR4G$SE>KF1[#%RD6];%49.V#P[I1N];J@IY
MA%""4#`!=]PZ@T.48*:9%;E[BXFJ'J?)@`DS%Q-5*50#F\Z@7TBADNDQ!3$Z
M2O040Z_,Z@)N)B`7L`PB`)^E;CC:>\C3YF<B>7T%B_-F/E.0^#,QKDQM:HC)
MM0PAAZQ2Z=.K5@;*P\N\N.0EWCJL4=PC'20MVS=9PI)KK'*";4Y_UE'6M*J]
M76MJO2)WGL,=<0ZCRAEKS*7A+/O&BO6+`>.*IQKQ*?)D:X<1&/X]O1*%<<F)
M8DH#>3:F7G&"'R4-/S:Q2N))VW=ID$$"`F5!TRT5=+TNW;7[3!_$_*69J'3.
M6W/VNYHXXP-AO4OD6WVB,N5+L,Y<;%7ZO,K2H+4Z(A7C=K58Z]7*=0:D2=+F
M*44D%5A\M$@ZJZIOETD77/C@<O'T=2.7'BL96BL!9?37RIC.#L'-2'M\IF@5
M,`\C\F9&0A;TWG4A:ELM%I3JM1)@3G7CPB+<ZR2"C[<3K>64`M!U>*\K165-
MO$DNZ)DR/CGB`\R#AB%XDXKYI\:XR587:KY)7@)7$ERQSEV7O=6>*GB)U1W<
M5(B\33NOH.^EH";02H@FF4H)%$QC"M\EZOS+X*S'XFU\-#VDAPKSAC#EIP@X
MWMN2$(:39#R`Y`UN[5[$L`E)TRY?16R%NN5D:2TS(261I^[NG)6Q7TNN<4``
MX$']!2@.5LBO7SW5*LQ">_22PM.)W+A-43O/4/R*Y3^=5<@1/#F/T#>4J0I!
M0`2OC)@F4=Q*42&*0=A`.\!DY^?A_9K_`),[R/$7D<*"2;WU`LWN%B'(<R[:
MDX^8;B0YM@(F1FJ`E,B(%,"HJ@)PZO=H//P_LU][+4MP3R:Y$AU>>G+0JW2H
MDH=M:(IJ0$'+U9XZ3;II,MDSG%4"D44%91$I0*0P)[$`5>;"TTL-4XWEZ%HD
M.".?'J\BHGZCO*=FDZ\E!FB@6I$^09-R%!-(ID6:`+O3*$W4==)%%0$0/OOO
MJ#,>@I7#'/U5?3CB5]0/D)<&LM2[=6FC.<B*D(P\S9(!_&1EM9+%24*$C5)=
M\629D!,AO-;I)&5\H#%,!(6DW00\P$4DT055.LJ"1")^:LIL*BRG0`=:JFWZ
MC#VCXCH'KN?3])1V`![0W\1[M@'V^W0K6JKHBV3,5#ST6_AI^+83,+)-EF4G
M%2S%O(Q<BR7(9-=I(,'B:S5XT6(80.FH0Q#!WAH75G5\DX9'@7T[_P#SV5F'
M/%[D=ESCA5[$N\=RV,HHL1D'&K5P^4.LNI5:W<"JJ50IU53F\MNX,B01`$RD
M(4"Z':N:B3\VBO;K?R.3/T[F4XD1CFCD_P`G,P0QA1,O5WF1Y"FU=\<4TR/B
M2$?5EFSURT?*)%,*/S12IE#H*.PFWM"@I;.I\%%7VWW->_4DXXX#X[>GYG^:
MQ'BJL4Q9HUH8K'CBR"A"HNLG49"2D3H/)%=%S*&9)"!G"A5%QVW$3=NZM>6G
M8SK@]13'F63U%HQKI>J[#H0&#+%@CT@Y97'V/&-DY%S?'Z?L#1^A6XQ_>OY?
MF<R[YV*$FW;N95U(UB/MXD2.54Z@@R+L&X`751;U/+/YMK-XN2?5I/422\7,
M&PN$.,6&\&J1#(S*GXUKL#/QKMFV5:OIQ>.2>6M5\S,15LN>1L#MTJJ!NL#F
M..XCWZ:'');GDM:NE6]%V&QI2%3*4A``A"`4A"%`"E*4``I2E*``!2@'8`!W
M::ST04T,+YNP%BOD-3GU-R;5F4TW<-EPAIY-NBA:J=*F25(RLE,L8)?4:W8H
MAP<%VSA`Y1*H4.H#%$Q1DFN1UT4Q[=I#YQ#L-_M'J7+4+,DTO;,J<5.*MXPS
M.VAZU2;N;6R-F-E*4C)"NQP\R4O>-I.+6?'(0NSH%!,/^3;4VKQ2;V:DU9<N
M!8/+IRYVMRVTC;?O)[=Q]GX_VU70R:%-QWVV\-]_#[^SMT?8)7:5[?=_7VZC
M7J^/U$Z#<?PW[A^/=OJ2-!V[?[;=OQVU&OM]@T.`*`(;]*G?MVIG`?N$N^VK
M05=H<0_<<M^SN,.X^("`@`CX[["&P:@LRNWL_/X[Z!0<1*7Q'[S?WU,LHU29
M<2.DGN_Y#^>FI>>[X$57K%U6QWCB-%TV$?0<-"V3.^&(^^V.SVV!I=<KE+)9
MC/5Y6;L%EE8:):QPSS2/0.!URF'SPZ0,(`&IJ[+;>#3Z6]*9';(I\#C3IC0E
M"@D(EO"0S>".V4@T(J.1A3LEB.&1XI)FB2..S73.HFNU,T*04SE,8#$V$!$!
MWU4RM)N7O)=M"1]NA!3;WC^'Y:".TC9B,&45'U0[9GZK9IQP-P><<X^DY*P4
MSM,:XR<F];R<8K"W.4J;1X,@PKR]>&-)\TZ2#J,F@!"B50IPE\H4]6AIOD?\
F98[5?/EH_P`O9_622;;WCH9H?65^WX:@0-"1H!]OP_+0B.T__]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g234488g64o35.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g234488g64o35.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`30$$`P$1``(1`0,1`?_$`,L```$$`@,!`0``````
M```````'"`D*`0(%!@L#!`$``00#`0$```````````````$%!@<"`P0("1``
M``8!`P($!`('`P8*"P```0(#!`4&!P`1""$2,1,4"4$B%0I1<6&!,B,D%A="
M5%?PD;'!,R6A\5)RDD,T)T<:HL+24X.31#:6-Q@1``$#`@0#!@,$!P4'!`,`
M``$1`@,`!"$2!08Q05%Q@9$B$P=AH12QP=$R\.%"4B-3%?%R@I(S8J)#TR06
M%[)SDT0T5"7_V@`,`P$``A$#$0`_`+^AS&+N(=?P#].VX]0`1VZ?`!'KX:Q4
M@X\%\`!^-(XD!1U'VU`OR9^X>X:<5<^9/XZY!QOR+F+IBB>&O6"3J-2H<A6W
MCT&J+OS(MW)9(AWZJ`IK@&ZC9(VX#TU:FA>T6X]>TB'5[6>T;;S-S`/<\/XI
MB&QN'9CPJ#:I[@Z-I-_)IUS%=.GC<A+&,<WJ$+I&GAQPP//G2&?^:=X!?X3<
MKO\`\%QM_JRSIT_\';JYW%BO]]__`"JX?_*6WOY-]_\`''_SJ[!6?NB?;JFY
M5&/FJGR7IC182@,U.XYJ3V-;]RA4Q,Y3KF19J4(F0#=PB5N<1`.@"/36J?V0
MWDR)S[>2RD<T*@>Y3V*QH7OI6>Z&W#(&R-NF-/-S!AVY7."=_=4X/'7E%@+E
ME0TLE\>,I5;*-/,L1JY?UYVKZV(>G3\T(ZPPCYNRFZ[)^7\WD/6Z*ABAN4!+
M\VJQUG1-5V]="TUJ&2"<A0'``$<%!!*A01Q[JG.GZE8:K#Z^G2MEBYD'@45"
M.7WTOA1W#QWVZ;]-^@!OOL```[^.FS$<:[L>)"5MHHHT45Q,[+(0,-+3CL%#
M,X:+D)9V5$@'6%M'-%7BX(E,8A#JBDB/:43%`1^(:SCC?-*V",?Q'N#0IP4E
M/C]E82/$;#*[\C6DD#C@%JMLK]T[P`2,X(.*N5JGIUW:`')1L9;+^D<+MS*(
M%/EM-02+&;F%/O*01#Q`-7+_`."=W>F'&>R:XC@72!W(\/23G5:O]U-!B)#X
M;GRHIRA.*<W#A\*L*8:R?#9LQ-C7,%=CYF)K^4J)5,@P478D&C6>CX>X0C*=
MC6DPU8/)%FWDD6CTI5B).%B%4`0`X@&JAO[273K^;3YBUTL$CF$M5"6N<,%`
MZ?IQ-B6=TR]M8[J/!LC`X`HH!X*A-*7KEKIHT44:**-%%&BBL".W^7Z!']70
M-(5X"CDIX"N"L%FK]4BW,W:)^%K<,S*8[N7L,HQA8IHF7<14<OY)9JU13*'B
M8Q]NFMD44MP[+;A[WJB!I*DE$P'7@G'A6N21D065S&#J3^G;2>8NS]A7.*MJ
M1PSEB@Y3_D:5;0=O<X_L\1;6%?EWC0K]K'2$C".GD>F[5:&!0$P4,;M'X:Z[
M[2-5TW(=2@FMS(U6B1N0D`HN4XI\<*Y[2_L;\/%E-'*6%"6D%#W8?=38_<"]
MQ7"WMP8UIN4<WP&1+)"7J\)4.&C\;Q5?EYLLLK&/)87#AK/6.M-0CT6K$_>8
MBRAP$0^4=/6T-I:EO.\DM--?%&^.(O/J$AJ`IB6AQ7IAB:;M>W%9;>MF75ZV
M1T;WY0&`.<J="YH^8IH/#'WYN)O.7D)4N-V),<<@8>ZW!A9Y-E+7BK4B+K#!
MG4Z\_LDBI(O(;($]))&6:1YDD0(U4`RYR%,)2B)@D6Y?:W7MK:0_6K^:U?:M
M+0C'/+O,X,"`QM&!*E3PIGT3?>D:]?MT^TBNFS/#B"]C`WRM+BI$CCP"#`J4
MJ;O_`"\/SV_7JM:FM&BBC111HHHT44:**-%%&BBC111HHHT44:**T$`W_#<.
MOY!_QZP(#LS3P(3Q7\*%0]WV?VUY<GO&N"O/="YJ+$**8)Y?>-OF_:,9A&LF
MRIMAZ=AS%W+M\->Y/;A6['TX$E?0Z]2:\O[R>NZKP(#_`!.GP`J1KVK?8?H'
MN)\3VG)&U<B,BXPD7V1KY24:Q4ZU4I.+*QIDHG&DD3.K!'.WIW3_`+^\2@;R
MRCTV^&H5OKW3O-H:\='AM8IHVQ1OS.>\'SA2$&`3E4GVKL2VU[2AJ,L[F$O<
MW*&M(\I3CQQYTA7NI^Q]DWVX*=%9MJN3#YMP$_L$;6)Z9?P*%>NV/YJ85!M`
M*65K'BI#2U?F'P@@5T@FW,W<'*4Y1`P"#OL7W.M-YW+]+N(!!J;6ET;`]SFR
M#FA<5!`XI3=NK9-QMYK+N*5TVG.P<H`RNY$@8)]O.FR^T;S-N'"OF]B&VQDV
M[8XWR1<*[C'-5<!RH2(G:9;Y9G#C*OF`'].,I3W[Y.0:+&_>%,@8G=V'.`N_
MN!MJRW+MB:)T;77T,9DB=P(=S"A"0&@^4X!5IHV9KLNA:NQP)%M(X1R#D2O$
M#D<1PKTQ\M9?QG@?'MGROF"ZP./<>4Z/-*66UV-X5E&1K4A@2*!C=IUW3MRK
MLF@@B11=PJ($3*8P@`^+]/L;[5+EEA81OFO'N1K6A2<3P`Z#$UZ8O+NWL+9U
MU>/#+=@XD_!4QYU6.S/]UKQWJLZ^C<(\;LF9:@63A--.X6BS0N+V$@@`&!RY
M8Q3N,L#_`,D#@'E"J9,ZA!`PE+OL%X:;[":[-"V35KJ*"9P7)&TRE/B0X(54
M%N*)58WWNMIT#R+6VDDB!P<7(#CV&N0P9]U7QMN-EBH7/7'W(^$(.3<"@M>8
M:R1.3X"&(H8I6[R891L5!2R$<GW=RZR15Q3(`F*F?;;6G5?8K6[>,NTFZAN9
M0"2QS3$[#HI<#AV8UML/=/3+B41WT$EO&[@Y<P\$&'QJQK:LC4Z_<;[CE'']
MHA;92+'AZUVVKVN&=I2,%,0SBI23UE)-'*`B59LHF&Y@Z'*("4P`8!`*9M[6
MXM]9CL[UACN&7+`6GB"'`8^/?5B2W$5QIK[JW>'POA<6D<",IQ%>0\U54=QR
M2Q@$RS\I'"G80.U5207%P8"%'Y02.LON!1#IL&OH.&QQ2Y@,JR(4PX-`'#X"
MO)`+W1Y0^3SX$9C_`'N';7KE8`=06,N)F$GMHE&%9KU'X]XQ4L$Q-O4(^,@X
MRO8Z@BR#Z3?/%$V[1LQ;M3'54.8`*!1$1U\_M4;<7FOW(BS27,UW*0,2I,AX
M?$KPKUK8/C@TJ"24AL;+9BD\``P'&J_O(G[I?B[CFV2]8P'AB_\`(5A%/5F`
M7LTW'XZITL=JY.@L[@/JL5+34E&J=@BDNH@V%0NQ@(`#JVM']C];O+9ESJUW
M#9ND`(9E,CD/[R.&4\,%-5]?^Z>F6\I98V\ES""07AP:%"<%#E^5(S4?NRL?
M.Y-LVO7#&]P4:ZD(]C]1KN5*_856I7[YNR!VNQ7JT:<Z"(N`,(%.!A`!VTYW
M?L+>,A=)9:C'+(QI)!B+<`"</,5)^7.N2'W9M9)?3EL98VH<3(#TZ-"?/E5H
M?*V?J'A7`=NY'Y`7D6..:/CY7)5A48,ROI9"`2C4I,R35D*S<CI^9)8I"$[R
M`8X@&X>.J.L-)O=4UB'1;/+]5++Z8S%!F5,3R'=5GW.H6]KIYU*=6V[8P\]4
M(_759K('W9_':(.Y+CKBYE:U-]N^/?W*YU/'I5TQ`#$.Y8F9V%9L8Y!W[/,,
M(!UW'5UV?L%KCT^MO88\%.5CG\TZM!/P'ZZK.?W:TQBBWM)Y,<#F:T'L.*UU
M&H_=HT%])-@N?#*[1-=<=G?,U?+%=L;Q$@J$(HNE&*U=@F\23`1$-ER;].H:
MZ+KV%N6M_P"AU*.28?LOB=&#R1<YK3'[M6V#Y[&1D//^(TD#J@"U82QG[AV`
M,X<,+MS=PX_E+OC:B42^6^<K8MTXBYQDQCR!=SD]1)V,74<)PUE2(W(38QU4
M>U<BI3&3$##45]M'6M+W)'MG4FMBO9)HV-<JL(D<&ARCB`OW]*L.TU_3]0T=
MVLV;O4M1&7$#B$"D=M>?[[MON0QWN4YXIF5:;5;WC*BU?%T53$Z/:;(5[ZF<
M2G)V6?6`$8?TT8=-TVEDT`,8IE-VX]P]H@`>L=@;*_[.TR6UN'P7=V^4/SL:
M%:!E(;YQ^\,4[.%4!NW=$6YKZ"XMS+#9,8%\Q3,5X@8'A3I/9[]Y'%_M@X?R
MUC>ZX1R!E*6R9E%G>&KVG34%&-6+8L#&UY&+71E&BJRST5T>[N*;M$#`'3;J
MQ^X_M[>;WU*#4;2\A@BA@<'!X*C]H\!\3_93ML[>-KMFVGMKB$R222-+2U`O
M'C@:EX^Z.MS2U<+>%T\5DZCEKMF1K9F48Z`BCAB@]Q1)S:[-VJF'9ZAFBZ!,
MW;L!E"]-5Y[&P.MMPZC&3F;':N8HPXR@`_*I9[I3-ET2SE(0NES)VL4]X6H$
M/9"Y!8<XH<S)WDCGFU-ZMC[%6!<G22RH)^OG9^:E6[&$BJO4HI(H*S-GFC2/
MEH-BF3`!'<YRD[C!;7N;I.I:YMUNAZ<,]X^X8T*4:&M(><W8BKQP05`=DW]I
MI.M.U#4'AEE%&2$&*O!;VE53H*G$M/W9U(;S;I"D\*KS-5Y-51-G)6/*U?KT
MJZ3(N=,KE:(;5>429"HD4#>4*Z@@.X=X[#JL8/82YDB635(O6RJ0R"1P:>CG
M9AV85-YO=9KIW,M+,F('`N<F8<R`G3@*EN]M7WK.-GN.V"6QG!0-EPYG&&B'
M5B'%]W=,9#^8JXR6;MGTQ3;+'IMF<\$6LZ2!XW,B@X;@J4P%.3N,6O=Y^W.K
M[.CCO)GLN-,E*"1C7!'<VN!X?C4OVWO;2MR2&W@#HKMO[#N)ZIU1/"ID_P`!
MWZ?Z=5[4QK.BBOF=0"E,81[0)N)C&$"E*4O4QS&$>TI0+UZB'36`.=V5I.;H
M!CV4J#G@*ZXI<ZBDKZ=2UUPB^_:*1YN,(H!@'8P"4SG<#!^`]=;Q;7/$LDR_
MW?U5AG8.8\:["DJFNF15%4BR2H%,15$Q5$CD'J4R9R]Q3E,'QWUJ*YBT@@BL
ME#@K3A7VTM%&BBC111HHHT45J(=?PWZ;_GTZ?IWVUCCF/8/OI"G/].%>5C[J
M4L$Y[DO.!Z`JF*ER3R9'$444*8>V'L#F,(8HEW#TO:V`"_$"@`:]T;'C,.R]
M.:,'?1L/BUI^^O+.ZBY^YKYRX_4R-[F\*NZ?;@18QWM4X?6'O$9F\97F^\Y0
M)YOKKF^+YA`#Q3-Y/RB/40UYJ]Y7!^^[F,?D9'$T=@8./C5V>V\89M*W/[3G
M/<>TN*UW+[@ZPURO>U)R71L!D!5LK:FU6MH.!3,=U:IJX0Z$(5L0X@8R[=T'
MG;E^8A4Q,'[.N7VFBEFW]8^BH(+BXC!&Y2OX=];]_P`L$&UKDS_E=E`'^TH1
M*\XRB,7LG?J+%QB2CJ3DKE5F3!%N4QUG3QW/1R"*+<I`[U%555"@0H_,(B!?
M'7L.Y+197#YB&QQQ2.Z#*C@[_=([\:\Y6[)'7=O;QC^.96!R<"1B/F6K5I;[
MICD_9IG,N$.',=,KHT:E4)EF>_QB2JJ36Q72UR\Q7ZA]8*`@F[;UB(K+MRW(
M8![7$B)]MR%$*0]B='BAL+K<KF`W)>Z&-W-N4,)+>A.9"1RJT?=359#=PZ."
M?3:QLC@.;B7#P1HP_&H:?;5S5[<^`[W<\@\_,27+.3E!I%,L34.-@F4]28Q5
M3U2EELMFBWCUF5_/%5!!"/(H)DD$2*'`!,I\M@[UTC>.JVL-KLV=EM$<SY3G
MRO)4`([$\57K4-VY?;;T^YEO=PPNFS`"-H"L'4EJHO1?C2+\]\F\-LJ\CI[(
MG":C3&(<-6*#B7;S'L\T:PJ$'="E.G.JUV+3=NBLX.1$I5?)*<4RK=_8!2B!
M0==J:=N33M)%GNF43Z@QQ&=AS^48C,Y/S=3S%-^OW>B7>HNFT-ACTZ4(6N"8
M\PWBC5Y=:M"^Q5FVQN?9IYN5V8F%'M>P<KF1C35CN@6^D0MCH#JP+0[4ZASD
M;L&+]=0Z20"!"><;8.NJ-]T-+MF^XFF2QQADEV(7/09<Q$F54&'``=U6KL2_
MGDV?>9W9FPM>&\T&0GGXU2XIZ`.UJBW43[O5.ZZAY?:4PJ'6<LB%#Q`ACG\P
M=O`/AKTA<.<8Y'OP(#G=X&']E4M`'#TRS\Q(^9(.'V5>O^Y;SI:<+<%,`\;J
MN]>137.MIC:]>5FBJC5>0Q_BBKL)61KBP)"'\++V9S$"X2WV410,D;<AS@/F
M#V9TN+4]V76N736O^C:7@'$9I7HJ<%".3HM7G[FWS].T"VTZ`EHFD:PH<<K1
MB%[PM56_:^X#RON-<J8C`J-H7HE-A:G*Y!R?<&#5%Y,PU.A7D9&!'U]JX_A%
M)B=F)5!J@HINFB0%5!ZE*&KTWQNV/9>A2:PR)K[E\I9&S@7.*H3U#0%3MJK=
MM:"[<>JMLXW>E;^EF<0,``4)`ZE>/5*MPVG[6[V_9>L(155N_(6GVA%-H8+=
M_/R-@\UVU$B@N%8&2CR1I@5<)]XIE$`+X`(:H"W]\]WQ7'U$T=K)'CY/3#<"
M$10>0-6Y)[8;=?'_``))V2$H'9\P/!<#A]B&I@N6F',$W'AI;\'<E\FK4/!+
MFBP-0R+>EK2PH;IY6X%&/(Z25GG)A0C5ILD6`*%2`YA`QBD`1U7>@WVJ1[AC
MU+18#)JGK%[(\N='%3P'$!:F.I6U@[1W6>IR!MD(PU[G(U0WGCU2JUSOF=]M
MCPZ8N(#"G'6(Y"V.'`6@35;QB]OGUE=OV`GZC(%Z.G&K*.3E`Q3@7M.&XCX;
M:N:';GO+N27U;R[=:1`EV5TGIAO%48SGB<.*56W]9]N-%;]-:0"XR#\P9G4]
M,SOM1*J]<Q<UXLY#\C,A9>PM@V$XY8VLZ\:E`XJKZ[5RTC!B6OI'4X]^G@6-
M0F["H`*NDFI2M4E"AV!N(ZO#0=/O](T-FG:A=/O+UK29)3P).+6A<?*,/BF-
M5CK%];:GJO\`4+.W%O`<,F"%2.(Y]:MC_;4X@A,U>WUS>Q==7<X6B99S%.XZ
ML#>&DSQ;]..F\,4J-L:\2]3*H9A(O8Z7(0RY2B.Z9>GRZH;WIU"32]Y:9?V0
M8VZMK=DK2BJ]LKG`N_>'\-N!XX]:M7VPM([O;=Y!*H@DN7,(&'E]-APZ8N/R
MZ56[]V;BYA[AASIRCQTP.%A)C>C5_&ZS$EKGU[)-$D['1H.>FTUY99))19$L
MA(J]B8E`$B#VAT`-7#L37-1W-M>'6-:<'ZA(7GR@-:0R1[1Y1AP1:K?=VD66
MB:S+I]D'?2L#4#CF/Y&N^UQ[L*F!]D7V;^)'/OBK8\W<AD<FJVN+S-8ZK`FI
M60756BT8.JF8*-DEHYJT<)JN0?B83*F$#"4`#4"]T?<C<>U=?&EZ&^&.U?:M
M<[-&'E7KFQ/+#ARJ9;&VCH^NZ5]?J(E,[97-&5Y:$`"8)Q"\>\4Z/[JP&-;P
MCP7QY''<>@ALA6T62:Z_GK"P@,<#!-%%A$`,X<>2<`,?XB(C\=1_V)>9=2U.
M[?C(Z"->GFE4X=M.7NFUK+&SM&_E:7(N)0,3CV55^X(\-[QSSY-8_P"-]&E&
ME;<6-21G;+<'S47K:ETVNME7UDL(M`$H.Y,C,/)9H")2KNCIIF$`'?5Y[LW%
M;;3T2?6;QID#7^5O[1E(1HZY<0HZ+56Z%HEQKVILTN!XC\BN<02`UH)&'7#`
M]4J6WW?_`&.Z+[<V`Z#GK$^8[KD2#D,@1F-+U`WYG$HOTI&P0LQ*0UCKKF(3
M2(DT,ZKSE%VT4`P$%PD9,P@!]5][=^Z-YO/6)]+U"V$+_0=(QS"4\KFC(['B
M`3CSZ5+]X[(M]NZ>R^MIWO!E#7!XQ0C#(1\<3\%%,M]CL90ONN</OI;D[=<]
MJOA7QB',0RL2IC*W_46I^W]I%79/<H]!$A1'J`:D?N@6'V_OF\&^FS`<%]:,
MJG7XTS;'+SNZV/$ASN/_`+;Z].WP_+J(_GXZ\45Z:KIUXO$#CRM2-JLKL&T;
M')B80*`&<.USCVMF3)'?N<.7*@@4@!^8]`UOM+>6\F;!`%>XH*URRLA87OX5
M%9=<NY<S]83P<`WF$HM94WTRFUPZI#%:`(^6XGWB)B>>J)1_>&,8J28CTW#4
M_MM/T[1K?U9LID12\XH>C1R=TIC?=2W;\C%`X5^A+B#FU5J5Z,-!)JBF*H-E
MI]$KWYB[B13<IP!8?P$WCI?^Y=):?2+W$'#%H3'"E_I]TX*2?&N'@KCFOCO8
MD63Q*8C43'*=:M6%19U`S*)`V4]&X.=1),0*`]JR)P[0'?MZ:SDM]-UUF6!C
M<X!0M1J'NI&RSV9RN!J4C%.4H'+-6;62#,*"A3>EEXEP8OK8B1('SMERE'JF
MH'SI*?LJ)B!@^.H%J%E+IUP8)0H7`T]03-N&9F?F'&E-UQ5NHT44:**-%%8'
M_6'^G2<"I_3]#1A7DI<T[&C;N8_*RTIJ)J(S/(;++\BQ-Q(8%KG*F*H8Y1$`
M$W;TVWWVZZ]];6B;%M[3[5ZI]'&'=F0)]@KR;KTSI=:NIBF9US*3VEQ']E6"
M/;0^X`X_<#^%^*N,MOP%FZ\V^@)V4\O/U-Q1&U=DWDS-/9AOZ`TY9V+X@&([
M`I^](A"B&Y1,`]*DWE[4ZKNC<<VMQW=O#;2%HRN;(Y_E`:2C6Y4*8>;PJ?[:
MW]8:#I,>DRP2ODC4@MRH02HXE5'`X5&C[IWN]Y?]S6:K,`^JC?$>!,?R:LW4
ML9-Y0TW+S=F5;';DM-\F&Z;=BZDV+0YB,F+?N;-1.<_F*'$!":;(]O;#9<$M
MPV1UQJ$[2QSRPM#6JH#`0K7=7*0<,,*C6[-X76Z7"S9$8K)A4!4<7?'%"."<
M*6GV$_;UNO+3EO1LYV*NO6W'CCC;8Z^6.S2+0Y(FX9$K2B<C2Z#`+*%(C+.$
MYPB$A(G)NFV9H"0X^8LF`MGNIO"TT/0)-+A>'ZM>1.8U@P+(W`-<]W50/+P\
MP)YX.&PMOW.K:LV^E:196SVN+NKFD$#O0+\.M.3^Z/P3;*KS$Q5R"-'O%<?Y
M=PW#4AO-E1,K&M;SC><L"DA`KK=O:FZ>5ZT,G2!3;&5325$G=V*=C/[%ZM%<
M[?DTE0+NVN))2.99(U@'E_:.=K@N"!.E=WNE:/M-79JC_P#\2:%L>9%1P<[#
MP(/?3(O:.Y6^WW@F<R#0O<#X]5O)-+O$K%SE,RT\I3G($GCQ\WCB1<E7I6%8
M`M,GK$L"*3I%=JW6.BX45\P`3,4=23?VW=XZK#%-M.\?;WT,9:^$.+6O:79\
MRA/-BB+R%,NT=6V_8.?::_;LFB)5LB*@08`=.?6IQ\F\^_MI*!`NY:NX!H^5
MY1JT4>-Z_0>/5G,Z<F(B(@W^IV&/A8)@H8H;?Q#I,H?CJL+':WO+>3&.:[EM
MXEQ=+./L!+CSX!.53:;<OMK`U8H(WN!X"-`"<$)<@"U)CFF-P'CWV7^2N5<!
MX+B..=-RSQ>M>3EZ$RB(Z(D6;FW5;RH]6P(QBSIHK+&8.D0,)%#D*`@!1VU#
M-/?JM[[BV6GZO=NO)K>]9"'J2,K'JC5Y*O;4JO!8VNS+F[L(600R6CWH`F):
M47N2O.IPQ$%E<E8@@5BI*%D+[CV'.DOW@@<J\_%MQ!3M[!^8WAL(==ORU["U
M5Y%K=.Y-AD/>&D^%>==/:MW;PO\`RF1@^*.=CCWX5=Z^Z@P?:[MQ<P1G&OQ[
MN1AL$Y5E65V%HDJJ$+7,G0K2':V-Z"13^3'L;)"L&ZJQ]DTQ>%[A`1#7F7V*
MU."#7KS29R`^[MQDY9GQG,&K\2ZKL]T[*6;3+>_;C';S^;!<K7Y5<1T"8U5K
M]K+GX[]N+E0RSFM3GM]I5BJ$EC?)-3BG3)I8'-2EWT1,(2==6?KMV/UF$EHI
M)8B2RB:;A-4Y1.41#5X[YVFS>>A_TUTC8-1;()(R?RAPS!S3\#F[\.E5=M76
MW[=U(W8:);4AS'%4!C)#@1\250U;0:_<[</+;8*'1<389Y#W>^9"MM-I</#2
M%<@*K',9>X6"/@RA*2LC.=IRQ@O_`#E`;$6$Y"#VB/CKS^?9'7X;:6_O;FRB
MLXF/+@'JXAN)*)S7`J.?&K;9[FZ'-(R&TCE=*][6(B(J]I4HG12%05%+]U!E
MC*4MR9P+@F8>23+#L-B17(D564EUB5ZR7J1GU(N3G'[<WEM)I]7FB)&[8JG>
M"'F"<I0.;?4_]B[#3X-&O-6C\VHF?T\R8M8UH+6YN#5.*HI.'*HI[J7=V[48
M+-Y_Z$PYLJH22Y"AYE$[NVH\/:6XT>W%GNPY3G_<'Y*PV'8/'B<*>G8VEKM&
M8W3R,W=IO'$O,+6J4`%7C>!5:D;GC6)0=J^?Y@G(!-AF6^];WMI;+>':5FZZ
MN9@7ND##(8BB)EY$K^=WEY)C4=VAI6WKV29^NW'HQP$98P<B@\G%#F'P"'GP
M%-;]Q>6XF2G+B_AP=BHF)XS0D-2JO1Q@T9U*,F9*!AP1MMC04LB[B7D1E)E<
M0%T801<>4!T@[=]W?9\>OLV["W=&8ZQ(7%SGEN?(YW`@(B8)A@>>--.X_P"D
M?U=W]##6V3&%$7%PYE3\#5QW[7*'*R]O.[S`)]JE@Y,Y$7.H'9W+%CJICZ+3
M..Q0$#%(V[>N_AKSM[Z3%VZXV'@RRB`_Q.>3WJ35Q^UK&MVXXCB^YD)[FQM'
MR%56?>_D9&1]U3EX:1343.TN5:CF7>54IC,65'KB;54A52AN4R'88!*)BF)U
M#;?5Z^VK6Q["L&Y26F)_F!X9I'%#AU)JJ]]2&XW7=A"US$&/,HT!.YH^=24>
MRI[T''O@7QOG..>8*#E>>N$[F1Y8*0YQ]`L)QE8PR)(QC%M%/%G4FP"%DH^4
M5[3"OVHJHB!B&$=RZAGN=[=ZMNC5X]:L)K=MJVWROS*",@)Y`\N?7IQJ3['W
MC8Z'IXTJ\C>;A\J@A$)=QXD=P"K2R?==6@\A:N#$0<J[([BJ91MSB*<"GZAH
M+HE?CR$<$()P*L@HZ,D8Q3"7N`0#<--OL-"UL&J3(3C$Q0/*F8D8]5`[:Z_=
M>3U)[&!'!CFO/'$*`#\J1G[5BL-Y/F?R`M#A$BJM6XZ*LF*P]3MGD]D"H$4.
MF;;8"J,6JI1#?<=_U:<??B9T>W[9C2?XEZYQ'+RQE.[AA7)[6,;-J]Q,?S"V
M`7_$`/E4OWW1TPBP]O.@1!@`Z\]RAQVD3N$P"DA&TC)\FLN&Q1\SM,BF00^'
M?OJ!>QD&;>$LV.5EG)XN>P+\T[*E?N<X';L41QS7,?\`Z7$_959;V`HU9_[L
M?&I0B0JEBHC+\JL)![B)$+CV28`J81*(@4#R/:'Z3!UU<_NJXLV#>./YB86]
MQ>UQ^;</@M5KL`9MU6J<,CW'M#7M%>DJQMM9DIR4K#"PPKVQPB:*LQ!-)-HX
MEHM)R&[<\@P25,Y:%6#P$Y0WUXV-O<,MVW+XWB%YP)!0GMKT>V:%\AA:X&5O
M$<ZC6Y*6V;RUEZ,Q963'<LX*12AV#<AMTG=E=%+]3D'':(@*,2W'M*(]``#"
M&P]=3O0+:/3-..I7"`N"KS0=/C^--=VYUS.(8TP.';3HBKXPXDX^9)N@]9/2
M10(<&I$E+!;9<I04<BD942BA'('\!.)4D4]MQ$P[C'VMO=R79+#DMVNQXY6X
M\^I/S[*[1Z-C$,R9CQ^--W<<YKB:2[VU%KY(L%-O1+2[P9(Z0&\!7],1N502
M?M"`&(7\=M/C-J6_IY#(Y\Y'$8!?C@<.^N,ZD_.H`R4XZLWG&/*>H2E8E8XS
M.6;MP._A'WEC+0ZJA`*C-0CL@#ZA`CC;M4)MX=JA0\!8+FSU#;USZJGTU&(X
M%"J&NR*:&\86'\R4SG'LA/<:\]&K,XL;Z-)/6\',*=QB-9&(D50"!L"*1C`4
M#-E5"@8>OED$Y?`-2F\9%N#2/7MQ_&8%/50/OX4WQN-C<9'?D)`\:EH*8#%*
M8I@,4P`8#!U`P"&X"40';80U79PX\J?.RMM%%&BBC116IO`=AV'X#MN&_P"(
MAN&X!\>OAK!R#$JF'#X%:*K%6C[7#B7;;/9;7)<A>0Q9&T6":L3X$C4$I4WD
MW(N9%R1(YJL"PI)K.3`01$1[?QU=4'OEN&WM8[1MI9ED;&M!1X*-"#_B<4&-
M5I/[8:1//)</GN`^1[G$*T@%Q4IY>'2N$_\`*H</MMAY#<BA#QV[\?;=P``%
M$V]6$3`&W@/0?COK8/?;</.RLR?\?_,3Y5J/M9I"(+FX'=&?F6&ENPS]LO[=
M^.)EK.WYUF7.BC-P5=.`O=S8PE15`AN\B3N*H4+695RGW`'<0TCY)PZ"GMON
MWW_O3O&[C='9_3V@<U"Z-KL_BY[FI_@!^)KMM?;/;T#P^Z,USE.#7EH8.YC&
M'Q<>RI[\?XXH6)Z?!8^QC3JW0:/66:;"!JE1AH^"@8IJGU\MI'1Z"#=,RA]S
MJ'[?,54$3G,8XB(U7=W=Y?SNNKV9\MRXXN<5/%4"\`I."5/+>VM[2)L-JQL<
M+>`:`!P3]#QKH7(7C?A3E5BZ>PWG['\'D?'M@!-5U#3:1P68R*`'!E-P4HU.
MA)P$ZP%0WD/&BR+A,#&)W"0YRFZ=)UC4]!U!NIZ7.Z&Y9S:2%'[I'`M^'4X5
MHU#3+#5+9UK?1,DA=R(X'J.AJM_D[[4OC3/SCM_BGDWF3&\.X,91"`L]<J^2
MR,Q44,<4$)4KJEOE&R1=@(5;S5``H"90X[ZM^Q]]M9AMQ#>65M.X%<S3(S-_
M?_U"2JE06A$&7!37-W[4:;,_-:W-Q%&JH0UV/P*-1OP0XXYL4'6:Q]IS@I%^
MW-?.766K-$`J;U\76\>5&H+O&IU`\QL$H]EK:#?U"0=IQ%`^P&'M`-=5Q[\Z
MM(W+;:?`QN'YI'N`(7A^1R8\%X\Z&>UEMYC/?3.C<BM#(VJGC5B3D'Q&HO(/
MB-;>&\E/62HX[M>-HG%BDU6SQIK'&5J&9Q[!IZ11^S<1YG1FL80AC'0,0=Q^
M4-4]I6MW&E;@;N*%L;[IDYERD'+F))0H02%)YK5@7FF6]_I3M)D<[Z9T882$
M!0`<%!'+H:A*HOVOG$FB7FEWICGG/S]]2K;7K>SCWXT(8]\[KDHWE6K-Z1"L
M)K>C77:E`_:<INW?80'J%FW?O?N*ZMY;9]I:@2M<TD!^`<""GG\*AD/MEHT-
MPRX$MP2PM(4LXM*C]CQQJQ_<J94\AU2Q4>]UV(MU.MD2_@[+69]@WE(>:AI)
M$S=_&2+!PFHBZ;.$3;"40_`0^8`'5.6]S=6=PV\M'NAN8WAS7-.((PJQ)H8;
MF%T%PUKX7A'-.((^(JL_G7[67B??;5(V'"6;LHX'B))9PY&C.(F)R?5XHZZ@
MJ%:P"DS(P-A9QK;O$$DG3U\H38/WG0`U=&D>^>N65NRWO;>VN`UH&97,>>*E
MY)>'..'`-&'"JSO?:S1[B3U+:6:($GRD-<T+P#0,B`8\2[\>4XP?;(X.P!FS
M&&:[/R:R;DZ0Q5<(:]0-80I57ID&]G8%55>-++J'D;6]7CTEU.\R:1D3F,4!
M[P'6.M^]FJ:MIMQID=E;LCGB=&YRYG`."*U`Q".2KV5NTGVULM-OF7K[F67T
MW`M;E:UJCK^8GN(YU+;[@GMK<;?<=H$'4,XQLU$V2G.W;['V3J6Y9QUWISI\
MB"3UHV</V$A'2U?DQ(073!XBHBH)`,04U-CA7^TMZ:QLV[=<Z?D,$P22*0DQ
MO`Q"AI&(Y%1WU*=P[:TO<<#8-0:<["K'M'F:?`X=M0-(?::XJ^I=[[FCD5U#
M`L0X-$,15=*3,F0X&\D9%:VO&I3]G03`UZCU[=@VU:3O?S4"S(S3;<7`:@>9
MG<^64!O#EYJ@9]IK0S%\EW,Z%Q5"T+XCE2V27VK7#!PZ2-%YVY'Q;5-DS3.V
M/(4&0.J]1+L\?&<J5!`0,^,81*F!.U$O3<WB/`/?7<I:UIMK+,W#'U245<?X
MG4#&NMOM5HC1D;/<`(1AE''XY:F=]O[@ICKV\<"'X^XRMMNNE</>+/?#3=V&
M*-,FE;2#!-ZU#Z,R8-"LVR<:F!/W??\`,.YAWV"MMV;HO=V:J-7U%D<<PC:Q
M&*&HU4P<25QXJF'"IKH&A6FW[+^GV3Y'19W.\Q!<I1>``3#I3(?<@]BSCG[A
MN24,VN;Y<\)9B4B8Z!LMLJ3&+L<)=HV';%9Q![-5Y59@)I>+9ID;I.&SQN`M
MTR@<AS`!PD^S?=#6=G69TYC8[G3B5#9"0YI5?*X8`8E06DJ>(3%DW-L73MRW
M`O'R207@`"M`(("\6E"3R7,`G$'C3&L(?:U88QAE/'^2;?RJR+?F^/[E7[FW
MJD?CNK5-E-/*W)MY:/9RC]>>LZOH5'C8@JE32(8Q0V`P#UU*=1]\M1N;*6QM
M;&",S1EI<7EY`<T@H$;BAP/*F.R]KK."YCN;BZED$;PX-RAN+2HQ5W?AX<:D
MB]QOV<,+>Y3DO'>2LKY5RK27F-Z7*4N%AZ,-:+%+,Y>:0FGL@\^N1$DJ+\R[
M<J8=AB%\L/`1ZZA&S_<+5-G6<]G8P0/;/(U[B_,2K0@`RN`1"I!!*\ZDVY-H
M6.Y)HKBZEEC=""!E1$*\B#UZC@*Y/VX?9^PI[:=SR5=L5Y*R;?'^3JU$UB5;
M7T:R9K'LXF2"326CA@H>-7\]98-C^88Y1*`=`'KI-X^X&K[TMXK;4(K>-D3R
MX>F'#$A"N9SEPX(E)MK9]AMF5\UG+(\R-#3G3@"H1`/OI7?<;]N+&ON2XWH>
M,<H7^^42"H5V4O3-:A_0@>R<H:#DH%)N^-.QTDD5LDUE51+V`0PG$-QVZ:;]
MH;ROMF7TE[IS(99Y8\A$@<?*7!^&5S4*M&)4(O:.W<.W+7<EJRTO'O9&QX<"
MU!B`1BH*A#XH?A3$.%?L@<1.!_)ZI\@*3R.O]DOU2B;17V=0NT_CQ%@Z2MC)
M-@Z]2QC8R/EO/;)HE%(H&#YP'<!Z;2O<GN9N7=.COTBYLHVVTA8<T;7KY,1Q
M<>.*X<Z8]#V'H^@7[+VVGE?<,!`#RP@JO1H/SY5)G7^*E`Q%FO+'*>-FYQS9
M;-7[$\<Q;M*)"-;&>%^J2)_6-V:;YZF*K4A6Y3F3.4-Q5,N80.$'?K%S?6<&
MB.;&(8WC$`YRIYXI\JE+-.MK6ZDU(%_J/;B"?+W!%^9I'.&4$%DOUSR)*B*J
MD6V7,@LJ3<I9.P.%7;QR*IP'8Q&/R]!`0^'33WN>0P6-OIT/^GBO7!$K781E
MT[YC7199K-<F.04C'-WBC:%:NWL<@[#<Y(:IPJ_E.7+9$.PBJLD[3,8@"8OF
M',7N$0#;76R6/0=&;*1_%<U?B7)@O'@:U$&]NC&OE!Q[/A3WT,!<>XYLC2G$
M#`N)1TW'M3D)CNM;[L(/>^(8'B+TR@`'</DD*F&W[.W345.L:X]YN07B$XX!
M&_V=_P"IT;;VS0(R`OQIC.0*A+<8,NP,_!/'CF#*N$O"O5P+YSJ$\XK>>KTB
M8A$2+KIH";<2``'`Z:H@!M2VRN8M>TQ\=R`9V@C#LXXKV@\J;)FFRG#V*A/W
MTL_-.OM)FMT/),84HBY`(==TF)`%1I)-_J4,(+`&X'07!42COX#IKVM))')/
MICCY<V'<4\*WZ@T.C;,..%/#P]8QMV,*/83*@JL_KL>+@P;?]H02!NOO\QQ[
M_,2Z]1U&=3M_I[Z:$'R!_*G"!RP-ZIQKL[JY5%B^",?6FN,I,3`4(YW-QC=\
M)A_L@T6=$7$WZ`+KG;#.]F=K'I_=-9&2,?M-\:["50IP`2&*;N+W%$!W`P;!
M\Q1#]HG4.H;AUUI)/`C*X=:V5]-94E(ODVT-8&3CD%[?+5LZ[$ZQ$(^,(_17
M`BRA175,9%0"&#]G;?P`-M.>GPNE4"-KQ\:YYB,`"0?A29&R-&[C_P!ZED#<
M1'I`E$/'X=K;8`_`/AIS^DD&!@C^58";J3\OPH#(T;_BK8_`0V&`#XCX_P"Q
M*.X?#1]*[^1'\J7U?]IW@*/ZC1O^*=D'](0`_P"I`P;Z0VCC_P`"/Y5@9&DX
MN>O=6`R'&_XJV4-QW^:"#?\`5W)%V#\@VT"S/\AGC2>K&.,A':OW5G^HL:`"
M']5K%N("&XP("(;]-PV0,7?1]&?Y$?C2B6/B'N/9^N@<C1V__P"T[&(`'0"U
MX!#]9A:B81_,1TGT9Y01CO\`UTIF:?VG?*@<BQHCO_5.R%#<=@"O_P"OTW=L
M'YZ3Z$<3;L+NN8_<16!E8O\`JEO<OV"L_P!18[_%2Q?F-?V']0`VV']>E-D'
M-RFW9_F/XUF)FI@\N[DK']1HX/\`Q3L9MP$![:^3;Y@V'H=$I=_B&P=/AMI/
MH3_(9XUCG!QSO^59+D2-WW#*=E`0VZF@4MAZ``_+Y1BCOMXB&X?#0+%.%O&.
M\X^)I2]HXO<.U3]E`Y$C0_\`%6QAO^,$4?#\-D#?C^>E-F3_`/7C\3^-+ZS/
MWR>P?C6?ZBQHAVAE.QCUW$2P!.[_`*1FY1*'Y#I/H3_(9_F/XTAE80@<X>%:
MCD6-#QRG9/T;P1"[=/P*EL/Z]9?1#_\`7C_S.^YU`D;E#<SRG96"Y$C?\4[(
M80V$.Z"3';M'</\`J=C=?QWWT@LB!Y((P>JK]I-+G')S_&M@R''=?^]*QAN`
M`/\`N$H[B&^X@!4#=O=W==@`.FCZ+#&WC+NJH?D16(>&8YW\>:'[5K(Y$C@Z
MCE2Q!X!UKX=NP%$NW;Z4"B(@/41`1$>OB`#I&V):$]!A'Q=^NE]9A"%[CX?<
M*U#(D8`B/]5;$(=.GT$QMA`-MP[FXZ7Z(_R&'O\`P(H=+&0A>0AXG[,*P7(D
M9T`N5+)T`>HP(F'\]S-QW'2&RP\UNP]Y_&@RQO<"V3'H`GVUO_42.`=_ZJ6(
M`V`/_M\-N@;;B/I=S"/XCN.D;9`?_78>TG[C2F1H.8.</"M?ZB1O0/ZJV,=N
MNP0(;B.^X[CZ<@FZ=.H[`'AK+Z+I!&.\_>:3U6\WO3N_"OROKY".63IL^RM9
M",W""B#DQHHC$`04`0.`.B^2*!A`=@,!BB.^V_76;+21K@Z.V8Z0<`H'VJ,.
MRATD;FY"XY3U_1:2(](P`HH<Q[(F8RJQ53J"S34,H=4-TSJ'47[UC;_VC"<H
M[^(]-.!NM8:S(6!H/!H(<O@.5<QCL@<P<!)R*TH36=I"5:7JS?)LTK63M%XQ
M9F+3U+-%BI\CAL=VH=51NB)1$``%"]@#L&P#KC=;W3GBX;;#U0055.?2MIDA
M##&KW-(X\JXJFCC*BL)6/I=YDHN/E5"'DD6#`'A%E"M3-TO,6\QUY8^G,(AL
M8@;>.MUY'?7%PT74+5`);CS/+%:Q880P^D7##']$K\M*;8EHCV0D:3=WD6_D
M6Y$)!PQ8IOE56_G`X`IP5.[\HAG``)NA0$>G36-W_4KEC8IH&EC."G\3W41>
M@P_PSY^9I!<YI4MF[C[O4K?)R5\<3Y'3UTJ9P1Z4&B('2=#^^,+==@[13*4.
MTFX;B4/#3MIOU`8ZWN(V"#(0,"<4X*J`=U<]T&9P^.0EX(PI>N9@`_Q?C.7D
MTP3FS2B(J)[%!4@R-=47E44T]@$A?4H)`;;8`V`!Z=--&V&ANHW$3.`)`^?C
MXUNU%Q^D:2A>4_3].%?#*YSN.&]"7>`'GD:T@Q!-N(]Q6RJ)#D[MQ`3(B.WQ
MV'6>EI'N>7#\I>$'/$#YT7&.G-S=!7&8:N$6PQ/78I_D&<@DR,WS=9BT8@9L
MU0%=0!\AV"7F=AB&$-^\1`1$=];+^V=_47N9`TN+EQ/`TMLX?3AI)#:_*>E<
M?7"BBJEA(Y46,"BRBK5%=150W[*RJBCHQG`@/CW=0UF^YUM@RY/+\'-Q_P!V
ML2RR49G"E.@;95:[&(Q4!E"?3BVAA3;-T&*;]!N7XM4%>YT)/)W_`-F'0--T
MEO</FSW-L&R'D2$_'YUT,?$P(U[SVI2\_P`Q-_Z7?S!_-$AZ?R]_YF]"3U^W
MUWT?=Z+M[.[N_<>'[/S::?0/]0]'(%_=7#\J\?G6_.WT<^;R]<>OC\*4Y9)`
MX]ZR:)@*4?F5*0VP`'<(=QP'M``#?3>"1P)QK>@IB&+>=V/LU6V,C<58*Y#W
M;&,Q:Y:G1?(B*QI#HX1?R$*\?,)"6:3DC:&5G<5%-_'JH$E21)FJRO;Y8G(8
M#BBO_>=XT%H&""GV"V:=/X5N)M]A#R4MP_2/RCL&ES/_`'CXT84`V;?W-#PZ
M[))=#?\`)V[=Q_/0KNI\:$%'IV?]V;B(!N(>2F.P!MOX%^`#OMXZ,SAS/C2(
M.@H],UZ?PC8!Z=P>4EL`CV_+W=H=1$W3IUTN9W4T(.E=>M-CJ%*AC6&UR,/`
M0H2$+$_4Y,46S,)*QS#"O0+(5#%W%S+3LHW:($`.XZZQ"`&XZ3,[J?&A!781
M;-`[=VR&X[^*"8>'41'Y>@?IT*[J?&A!TK(M6VW1JW'J&^Z*7A^(;%'?;0'.
MZGQH05KZ=KMOZ9L&VPCN@3?;^T&P%W`0#2YG=30@K;TK;?8&K?P'Q0)MOTVV
M'L#<.NC,[J:$%9]*U_NK<?\`X*0;?'?J4/A_PZ,SNIH05@&K78-VS8H_AY*8
M]1#PW[0WT9G=30@K46S7M[O2MQ+X]&Y!';\A*`]=)F=U/C0@K)6K01'^&;=/
M$012\?\`HZ,SOWCXTJ"M_2-?[LW_`/DI_P#LZ,SNI\:1!6!:M``1%LW``ZB/
MDI]`#J/@72YG=30@I&*]F[&MHSGDCCQ$E>GR-BFF4&^7!NM"^3#MX')+BPMZ
ML9E*F-Y;UXN>KNQ52*4!2`I=Q^;29G=3XTN4(M+.+5J'_P!,W\.G[@@_GT`@
MCHS.ZGQI$%'I&O\`=F_ZT4P_]7II<SNIH05J+=IV[@V;COT`/)3#<?#;]@?[
M7QT9G=30@KX.XJ+D&SE@]CF3EHZ1.W<MEVJ1TET%BB15)0IB"4Y#D-M^GKI1
M)(TAS'$.!XTCF,>,K@"TTV%YPMP(]E3R?T&>:%46%8T4PMD\SA1`_4R1(U)Z
M"*38^X@*9>THA\-M/L>YM6CB]%KF(B+E"^-<KK"V<5+<.E+7)T&O,<>2],KD
M*PC(X*W)QD:Q:-DB)I"JR6*B!?E$QCF6$!$PB)A'KOOIJCNI77K;J=SB<X)Q
M("<^%;S$P0F)H1B4QWA'+-B2%_H$J5/SW;9O())+@"AC*,O.B95-,RH&,!B;
M@80_#KJ5;GB+8K>]9@'?$\,$/?39II)D?&X`=*3O']C#CMGFRPUG14_EY9Z\
MAY4RA/.\J'?NQD(.<13,4PF2;D.7O`G4Q"G``W#75=VS=7T>-]GA.UJX$E3T
M./'E6J.3Z:[+9!Y24I\Z^'<%V*?2RNI&PCQR91K*#)I2X$KSQPB1)1O)/&17
M`1JCA'MWW4+ON'7KJ,,U/6;:!VFQ%[05!"*<<"%*G%?PIR%O9N?ZP`Z\>^F4
M<D<C$S3?JW1J.H,G&1CX\'&.FP&%.7L4NJBV>NVINT?X&/13["F_9$I%#?L[
M#J2:)9.TRT?<7/EE<TN)Z`!4/QXX=:;[N832B&/%@(I7.7KYC3\3X^QPT4)W
M%79*>7N`*$CZM'>F*<X`(`5)19QL`[=1(.WAKCVW_P!5JLU\\?PSF_WBI\$P
MKHOAEMFQ`\"/PIR>"ZFVA\-46&D&"!U%:VW4?H.D$E!4&2(=PJFJ!RB)BF36
MV$!\0TPZK.7:C*Z%Q`:[#'I77;L`@#2.(KH$EPPP))RJLJ:OS3$5EQ<*QL5:
M9R.AS'%05#%"-;O"H)IF$=A*7M+MTVUULW'JC(O2+FN^):%[:U.T^V<5+:</
M7JA6:I$,X*NPL?%1+`@)MF;5LD5,@?VC")BF,<Y_[1A$1'3/+<3SR^K,]SG?
M$UUM8QH0`5V#R4O+\KRD_*_]WV%\O]KN_8V[?VNOAXZUJ57G2H$3E63`40$#
M@42["`@;80$!#80V'IU_3^.DI:AXKP77VM;U0,:NGQK_`.W[F?*K?'V,%G*@
M_P!0N(V2,CRDD_K./7(&,8;Q@6RS:BC2*<!_O"O.54VZH*-134T4I*E:DXS3
MCL<LXBR7C%.9E:\O>Z38ZLRL$+(NXJ6@I&5BW+6-FHZ28'2>,W<4_.FN0Y!`
M0,F'Y:*2H9*MFK(G*_!O"SA^2Q62#RY9;;*5_E].04K(1MIJF.N(%D9PV4QD
M)AB)7\1)9GG&$/'MU^XIS$L`J%W`!V*RRE,W*IP+S"3MBI5PK]8LKBGV2<K<
MY%P%L:MT7;FLS,A&N&D7.MFBP>4X5AW:B:Y2&Z',38?'16-17>VO7J9BV>LN
M`,EX_L&.N;>+<:UA/+\G+WNV7:#Y%4R1DW+)AR3H$S/2[UC,5^]VN%=F=I@W
M;/Z_)'4C7!"@1/N*4@`X<*Y[W?L>5+*''7$=8MC19R27Y?<7(EAZ:9EXD`))
M9;KXS21E(ERV,X4=UYJ[23[]P26,14@E4(0=%)4C^,\:5##U)AL>T5D]CZK`
M)KI1K.2F9>?=HI.'!USE4E9U[(2;H/-5-MYJQQ`-@#ITT45!8:'SIRVY.<RY
M><Q!`9VJ&%<TN>/V.*=,\@Y[%#/%]?KU8A)=_8V5.KQT%_YNNCZ:!VC-N3',
M=!%,C<"E3-HI2`$J6/A32<_XYXXT6D<EK$QL^5*TYM$>XF6<RXLBRM0&TR[F
MA,)>PN6S1:=L$)2UF+!Z^,F4SI=L98=S'$1*2F1../,)R@]QKF"SRY;<B3N&
M,;8.XI047AEC>['7Z$\O]C4SY+2MX?,*[)QCT9F,@#-&Z(E5(F<RQCJ%.9-(
M2E9`D"F*5[`#*;]KKD%R0NN7<YW3+V(7O*6)XRY%F<KV1A9<-UGCYF_(]$P7
M!PKF,D&T9*+,V]-9%DWLD@\<RQ%E06'Y@V*"5JR717$B]H],>3*_JI=W5*\Z
MEG(@4/42*\.S5?+]H;`45G)C#^`;Z*QJ'ZB4>*PGSSGH_EI!VJV7+.V9[)>N
M'W*$URM)ZDX8A#^MCN+T[6&<JVK]&L%%B&SD(E!9JHTL;8#J$4%RD8@%*@11
M4UI0VZ_CN/Z`\-]OT#MHI*VT45H?;;](CL&P[#OL(]!^`@`#HHJ,S`(`\]SK
MW!I`$53'B\8\1JQZHX#Y92IU&V6,K%$V^QB)#8A5-\>Y;1RK(_E%?B]T^,O%
MLQWQ;QUCW)5RQ-/9,YP<?:@\NM!EE(>R,:JX5L\C;&K9T0=C(R</'J-CE,4Y
M2^<!^T1(&E%#>/=259&X]4GB;RWX(3O'N2N].DLM90O6,<M0DCD6X6:O91I"
M6,K+9GCJTP5FEY9D[LT1+QB+UH^0!NHBH!@$!*;M`Y4JDM-/UYMY:MF!^(?)
M/,M$2;JW/&F&<@7"KF=MQ=LFLY"UQ\\CG[]O_P!<PCG295UR_%),VDK`8%:1
M[C#P?PGC^NX?RBK-73*>964-&W.;SQ9,D7*:F<E6BV5E8+#9))H,Z-8=0<\>
M?<+M&2;,&;-,R0(%+Y93:5:R+B:D"*.XCX#M\H_H$-AZ_I'?P^&DK&MM%%1/
MY.:S''GD*2WQ#?\`W/*/5K%'))E$C9]&2)O*L<.8?#S4S"/;^`B!O#5@6+FZ
M[HSK7`W#6AO9EYCMIDF#K6Z$@_*JTZ3*F)JIR4J<)?J/*LFMB^G@>+E#%`S:
M1;=3'@YL$A%5%5JX$2@?83I&W#]DPZCVGZG<:#=.M[C\BIV?$=:[988[MGJ1
M)F2F4*<:\]-G!X0E4?F;J'[-FL\3^7U``_;WCVNBM4TE`Z[&+N`#J4G7-)>/
M4S`2G%4YTVNMKT'*P8&GCX-X]Q>&D7F1,AR,<O8&,>Y,D<BI?H]58>7W.E4U
MC@4',FNB7L%4``"DW*3?NU&M5UEVID65B"(0<0%5Q[.793A;6C;8>K,1F^0I
MKLK(O^4.?HYLS15"M$710124`W\%2X=R+AT]7+U`AI=0WAX]Z_;X%T_QQ,T#
M129D$SQ\W!`!UQX]*XG2&^N\C/\`3!!6I:$&Z39%%N@0"(MT4T$2`'1-)(@)
MID#]!2%`-5Z5)))Q)I]P`2OMHHHT44:**_#)1[66CWL8]*<[20:.6+HJ2RS=
M4S9VB=NN5)PW42<(*&24'M.0Q3D-L8H@(`.BBF+U/VY\#5VXT&W3UCS=E-#$
M\V>SXNIN7,O6B^4>BV?L72:V./@Y)0BL[-Q:#I0C)Q-+RAV?>)D>Q38^BBG9
M90R"ABZGR=S=5.^W-I%G;"YA,9U"9OMQ73<K`B96+J=>;/IN5].(@90C=$YR
MD'N`H@`[%%,)X!<>)2!R)RHYE9`Q<^Q%DOEYDAK.1V/9U8BUEI6+:C%,X&K!
M9&B3MXR@+G>U&8RTXR;B4"*`U(N`N$3@4I54)4A=\I<9D2F66CS3R<CXRTPS
MZ$>R-9F7U<L+%!\B9$[R$G(U5%_$2:`F[T5TC`=-0`$/#124@^$.(6,,&7:S
M9/C9C(F0\I6NN15*DLD99N+JYVMM1X1\YE8RF0ZPMHZ,AJZWEGJKLZ3=JFHX
M<G\Q8Z@E)VE*2N-=WY"<>L;\F\;N,7Y0:3"L",_6K9%2-<FGE>LE:MM-F&L_
M5K/79ID/FL)>%EF9%4C&*HF;J4Y#E$2B4E=\QY2F^.J97J6UG[3:4:]'IL"V
M&[3`S]JF!((F,^G)?T[0KY^L8VYCE23+^!0#1138\F\$\-Y%RE-YJB9[*V'L
MGVZ$CZ[?[3A7(,A1CY%B(=-1&%2NT,+:4KLQ(PJ"ZB361!FE)I(J"GZ@4P*4
M"E)6G34FGQE"J5?ID,YF'D77(MM%,W=@F']@G':+8G;ZF5FI19P^DWRX[F45
M5,(F$>FP;`!25U.IX7H5)R7EC+E>CW36\9J)14[](K/W+EO(DQQ%2D/5"M62
MIQ08%9,IAP!P2`OFF/N;J&BCDE)>APWP2VXWV?BBVK\HAABWN[J]G(-*>D"R
M+A?(5]ELDVD4YKS!?)$D+5-N5=@'Y4U.SPT44YMFR08,V3!L!B-F#9!HW()A
M-L@W1*@B4XB.YQ*F0`W'QT44S>N\$</0^4*WE:=LN8<DRE$LDO<<;5K)F3)B
MV4K'-JF_/(ZGZM`KIMC&DFK5TJBT/(+/P9)*""`)FV,!2K@E*%A#!E@QE?.0
M&2+?DZT9#G\X9#:V./B9*0D`J.,Z17X1K!U.ATNON':[&.(U`KIV_>)$25D'
M3K=0-DD]%)3D=%%8$`,`@/@/^7Y:**1^G8*QU0\KYAS57(QZUOV=5*0KD617
MDWCIG)&Q[5F=-K'H8U90S2+*T@F*:9P1*4%3@)S;F$1T4JX)7WR=A+'^7Y/%
MLO>(YW(/,.9'B<KT4S:0<L4V%TA&,C'1L@[3;&(#]N@UE5@\A3=,PFW$!V#1
M0"E?:ZX:H>0+[B/)-GCG+RU8/FK/8,>N4WSANUC92WU9[3IIP[9)F]/(^9!R
M"A$@4`?)./>78=%"X)2@3<)$62'E:]8(QA-P4Y'/(F8AY5HB_C)2,D6ZC5]'
MR#)R51N[9/&RIDU$SE$IR&$!#8=%)32\+\(<7X"LD!*8XN^<&51J",HTIF(I
MG*T[8L5U)A)LEH].,AX*9(\ECQ4*S7,2.;.I!R@Q*!`2(4$TP(44OJV*:POE
MQCFH[JS!;XZ@N\<-V*=HFDZ>:`>SQ+$NZ7II785]Q8?J"8%+(G0%V1#=(#@0
M1`2BE+$-PV'P'H(?B'X:**2',N)(G+M16@G:A64LS.+VO3()]RL9(%()0`>W
M8YV3HO[M8F_S$'?J(!IQTO4)--NA.U<G,5HN8&W$>0X$5&+#6O+W&BT/X82*
M1X><)WT!)HKKUF<3[Q*61BU.XH)E53#Y5D#@;NZ')J<NM=,W#$'L3U$Q/,=G
M7L-,K)9[)Y:5(_3MIPZ/.M4&@`OC41D>SY_(L*0,3J=H%`^ZC,KH$A-X_NS=
MH?$=,YVC$V3_`%7B/^YR_P`U=7]5**6A4Z_JI`KKEG+/(25:5=JR5,S=+%,Q
MI]<!;T[@Y#@'JI9WT5=I(;[F44[4$P+N)=@$=/%OI>G:-'Z[R,_',[B4Q&'`
M"M#[B>\`:`C5J0;C[@]MB*OK+22B+VYSI4E)Y^B`&1:D()E$8E@<2[^F;B<>
M\P;`JKN.WAJ&:QJC]1E$;%%LP^4'YGOIUM+<6[.`S&G$::*Z:-%%&BBC111H
MHHT45K\>GCT_S?K^'Y:**S^._AM^KPZ[;==%%9T44:**-%%&BBC111HHHT44
M:**-%%8-X?KZ>&_ZM^F^BBC_`$_\7AHHK.BBC111HHHT44:**-%%&BBC111H
MHK4VW:.^^VW7;NW_`/1^;_-H"\N-%)WD?^F'T$W]4/Y8^A[J^3_,GI?]MV!W
M_2O-_B_6=FVWI?WW_)ZZZ['ZWU/_`.?G]5?V51?CR\:TS>@G\=$^-,A=_P#\
M/?5B;?6>SS3?]F_G'Z/OW#W[>?\`O?*_YG3;PU*Q_P!U>EBB)7"[Z#,>GRIX
M6)/Z,?2E?Z1_ROZ?RD_6_1NSZMV]/+^J^J_WMW=WAZCXZC>I?U51_4L_PZ?!
M$P\<4KMA]!/X"+2O].FV_B&_AX;?'?X?AMTWTUA.7&M^/.M]944:**-%%&BB
#O__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
